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Although microarray technology has been widely applied to the analysis of many malignancies, 
integrative analyses across multiple studies are rarely investigated, especially for studies of 
different platforms or studies of different diseases. Difficulties with the technology include 
issues such as different experimental designs between studies, gene matching, inter-study 
normalization and disease heterogeneity. This dissertation is motivated by these issues and 
investigates two aspects of inter-study analysis. 
First, we aimed to enhance the inter-study prediction of microarray data from different 
platforms. Normalization is a critical step for direct inter-study prediction because it applies a 
prediction model established in one study to data in another study. We found that gene-specific 
discrepancies in the expression intensity levels across studies often exist even after proper 
sample-wise normalization, which cause major difficulties in direct inter-study prediction. We 
proposed a sample-wise normalization followed by a ratio-adjusted gene-wise normalization 
(SN+rGN) method to solve this issue.  Taking into account both binary classification and 
survival risk predictions, simulation results, as well as applications to three lung cancer data sets 
and two prostate cancer data sets, showed a significant and robust improvement in our method. 
Second, we performed an integrative analysis on the expression profiles of four published 
studies to detect the common biomarkers among them. The identified predictive biomarkers 
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achieved high predictive accuracy similar to using whole genome sequence in the within-cancer-
type prediction. They also performed superior to the method using whole genome sequences in 
inter-cancer-type prediction. The results suggest that the compact lists of predictive biomarkers 
are important in cancer development and represent common signatures of malignancies of 
multiple cancer types. Pathway analysis revealed important tumorogenesis functional categories. 
Our research improved predictions across clinical centers and across diseases and is a 
necessary step for clinical translation research. 
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1.0  INTRODUCTION 
1.1 INTRODUCTION TO  MICROARRAYS 
Microarray analysis is a technology used to simultaneously monitor the mRNA expression level 
of thousands of genes. (Schena et. al., 1995; Chu et al., 1998; Golup et al., 1999; Garber et al., 
2001; Huang et al., 2003; Potti et al., 2006). This technology is based on two fundamental 
rationales. First, according to the famous central dogma of molecular biology (Crick, 1970), 
expressed DNA sequences are transcribed into mRNA before proteins can be synthesized using 
the information in this mature mRNA as a template. Second, because of the double strand 
binding property of complimentary DNA sequences, complimentary hybridization can be 
utilized in microarray technology to measure the expression intensities of the target mRNA.  
There are several microarray platforms available, including cDNA, Affemetrix GeneChip, 
GE (Amersham) Codelink, Illumina, and Agilent. They generally belong to two types of arrays: 
the two-color cDNA microarray developed in the Brown and Botstein labs at Stanford (DeRisi et 
al., 1997, Eisen et al., 1998) and one-color oligonucleotide chips from the Affymetrix Company 
(Lockhard et al., 1996). The cDNA microarray probes are DNA fragments usually amplified by 
PCR and spotted by a robot on a glass microscope slide.  The two complementary DNA samples 
are obtained from mRNA by reverse transcription and the relative abundance of these DNA 
sequences is assessed by monitoring the differential hybridization of the two samples to the 
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probes on the array. The two cDNA samples are labeled with a spectrally distinguishable red 
(Cy5) or green (Cy3) fluorescent dye. After washing, only the bound strands are kept and the 
ratio of the relative fluorescence of two dyes will be used as the expression intensity (Schena, 
1999). 
The probes of Affymetrix GeneChips are short oligonucleotides that are synthesized using a 
photolithographic approach with a length of 25-mers (Pease et al., 1994). Originally, 16-20 
probe pairs, each corresponding to a different part of the sequence for a gene, make up a probe 
set (Bolstad et al., 2003). Now, the number of probe pairs is reduced  from 11 to 16. The samples 
are labeled in one color and have their absolute intensity measured. The intensity information 
from the value of each of the probes in a probe set are combined to get an expression measure. 
Detailed Affymetrix microarray technology is described by Lipshutz et al. (1999) and 
Warrington et al. (2000).  
 A lot of comparisons have been done between cDNA array and Affymetrix GeneChip 
(Yuen et al., 2002; Li et al., 2002; Woo et al., 2004; Park et al., 2004; Irizarry et al., 2005; 
Larkin et al., 2005; Kuo et al., 2006; Shi et al., 2006). In general, the Affymetrix data have better 
accuracy and precision and are more reliable for interrogating changes in gene expression than 
data from long cDNA microarrays. The hybridization of a cDNA array is less sensitive and 
specific; also the image analysis is more difficult and the data is noisier with poorer 
reproducibility when compared to the Affymetrix GeneChip (Li et al., 2002; Woo et al., 2004; 
Irizarry et al., 2005). Affymetrix was proven to perform the best by the MAQC project (Shi et 
al., 2006). However, because it is much cheaper and can be custom made for special species, 
cDNA array is still a popular tool for researchers. 
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Since microarrays were first invented in 1995 (Schena et. al., 1995), they have been widely 
used in biomedical research such as gene expression studies (Brown et al., 1999), cancer 
diagnosis (Golub et al., 1999; Yu et al., 2004), prognosis prediction (van’t Veer et al., 2002; 
Beer et al., 2002), and target drug treatment (Shipp, et al., 2002; Potti et al., 2006). The keyword 
“microarray” in the public database PubMed yields over 25,000 search results and the number is 
increasing quickly. We expect that microarray technology will be more useful in the future for 
disease prediction, diagnosis, prognosis prediction and treatment selection, especially in clinical 
medicine. 
Unlike the traditional data structure in statistics, microarray data have a very high dimension 
with a relatively small number of samples. Software and packages have been developed to 
process and analyze microarray data. For example, dChip (Li & Wang, 2001) and MAS (Irizarry, 
et al., 2003) are specific to the data processing and analysis of Affymetrix data. SAM, K-Means 
and PAM are commonly used R packages for various purposes, such as detecting differentially 
expressed (DE) genes, clustering, and prediction. With the adoption of machine learning skills, 
analysis of microarray data is more feasible and powerful. Recently, the trend is to use gene 
modules as basic building blocks instead of individual genes and several new methods have been 
proposed (Lamb et al., 2003; Huang et al., 2003; Segal et al., 2004, Segal et al., 2005; Tongbai 
et al., 2008). These methods, including pathway analysis and module map methods, help to 
explore a high-order and more interpretable characterization of transcription changes; also, 
patterns too subtle to be detected by a single gene can be detected by the large module consisting 
of many coherent genes (Segal et al., 2005). For example, Ingenuity Pathways Analysis (IPA) 
(Ingenuity Systems, Redwood City, CA) is a popular and powerful analysis system and database 
for pathway analysis. However, research in microarray studies is still facing several unsolved 
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problems.  For example, with more and more microarray data sets available, the statistical 
analysis of multiple microarray studies is important, but challenging. This motivated my 
dissertation work, which aims to solve two problems. The first problem deals with the cross-
prediction of studies involving the same disease from different labs. Literature investigating the 
same disease with different array platforms or in different labs is often reported with similar high 
disease prediction accuracies without mention of direct inter-study predictions.  Many technical 
difficulties exist when attempting to directly apply prediction models to independent studies. Our 
objective is to develop an improved and robust normalization method for direct inter-study 
prediction. Our proposed normalization method dramatically improves the cross prediction’s 
accuracy for studies of any microarray platforms. Chapter 2 focuses on this proposal. The second 
problem deals with cross-prediction of studies of same platform arrays from different diseases. 
Multiple microarray studies for the same disease are very common. However, meta-analysis to 
integrate multiple studies has rarely been investigated. In this project, we performed a meta-
analysis on 455 arrays collected from four microarray studies in the Affymetrix U95Av2 
platform in order to detect the common predictive biomarkers in the microarray studies of four 
different cancer types. The identified predictive biomarkers achieved high predictive accuracy 
similar to using a whole genome in the within-cancer-type prediction. This project is the central 
concern of chapter 3. In the next section, we will introduce the background of these two projects 
in details. 
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1.2 OVERVIEW OF PROBLEMS CONSIDERED IN THIS DISSERTATION 
1.2.1 Normalization in inter-study and inter-platform cross prediction 
Literature investigating the same disease with different array platforms or in different labs is 
often reported with similar high disease prediction accuracies. These studies either compared and 
validated the DE genes or the biomarkers independently found in each study (Tan, et al. 2003; 
Shi et al.2006; Mitchell, et al. 2004) or evaluated inter-lab or inter-platform concordance by 
correlation (Parmigiani, et al. 2004). The direct application of prediction models to independent 
studies was, however, rarely investigated. For example, literature investigating lung cancer with 
different array platforms or in different labs is often reported with similar high disease prediction 
accuracies without any mention of direct inter-study predictions (i.e., establishing a prediction 
model from one data set and applying it to another). The major difficulties for such direct inter-
study prediction may include: (1) biological differences in the sample population across studies; 
(2) different sample preparations and experimental protocols; and (3) different microarray 
platforms (Fishel, et al. 2007). Different data preprocessing and incorrect gene matching across 
studies have also been mentioned as having a great impact on such inter-study analysis (Bosotti, 
2007). This creates a barrier for the progress of array technology from beyond bench work to 
prospective clinical use. Suppose a pilot study or a clinical trial has performed in an old 
Affymetrix U95 platform and an effective prediction model has been constructed. The test site of 
another medical center may apply another commercial system (such as Agilent or Illumina 
platforms) or  the original medical center  might even migrate to a newer U133 system. The 
translational research of microarray would not be successful if the prediction model cannot 
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predict inter-platform or inter-lab studies. This happens often because of the variety of 
microarray platforms. 
Of  the difficulties mentioned above, some can be overcome by applying consistent data 
preprocessing strategies or improving gene matching across studies. UniGene cluster ID has 
been commonly used as a gene identifier for gene matching (Parmigiani, et al. 2004). However, 
it often happens that a gene can have multiple UniGene IDs, and many genes could share the 
same UniGene ID. All this adds to the difficulty of gene matching. Entrez Gene ID turns out to 
be more unique and becomes more recognizable to researchers (Maglott, et al. 2005; Bosotti, et 
al. 2007). In the other extreme, if the intrinsic difference across studies is indeed large due to a 
differential sample population or to experimental protocols as mentioned in (1) and (2) above, 
the direct inter-study prediction will never be valid. Inter-study normalization is a critical step for 
cross prediction because it can bring the gene expression intensities from different studies to a 
comparable level. In section 2.2, we will investigate a commonly encountered situation in which 
gene-specific discrepancies in expression intensity levels across studies are found even after 
proper sample-wise normalization. We will compare the intensity levels based on the raw data 
and the data after various normalizations for a given gene across three studies. The gene-specific 
discrepancies often come from differential probe sequence selections and experimental protocols 
in different array platforms that cause different gene-specific hybridization efficiencies across 
studies.  
In section 2.3, we will introduce and compare the current sample-wise normalization 
methods and how  most of the time they are not sufficient for inter-study predication. To solve 
the gene-specific discrepancies, we proposed a sample-wise normalization followed by ratio-
adjusted gene-wise normalization (SN+rGN) method. The classification information for  the test 
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data is unknown, but is necessary for the ratio-adjustment gene-wise normalization. Thus we 
introduced the calibration idea to get away from this problem. The calibration scheme for a 
prospective study will also be  detailed in this section. 
In section 2.4, we will show the inter-study prediction results after applying our proposed 
method to three lung cancer and two prostate cancer data sets, considering both binary 
classification and survival risk predictions. Two of the three lung cancer studies are from the 
Affymetrix data and the third is from the cDNA data. One of the two prostate cancer sets is from 
the Affymetrix data and the other is from the cDNA data. Our prediction tools for binary 
classification include PAM, LDA, and KNN. SuperPC was used for survival prediction. Our 
proposed SN+rGN normalization method yielded significant and robust improvement for the 
inter-study predictions compared to the sample-wise normalization. 
In the last part of chapter 2, we will discuss our proposed method and its application. We 
will show the strengths and limitations of rGN and how it can be used in clinical studies. Finally, 
we will draw conclusions from this study.  
1.2.2 Meta-analysis of different tissues in same microarray platform 
Instead of studying data of different platforms from the same disease as above, we focused 
on meta-analysis of different diseases from the same platform. Human malignancies can occur in 
almost all organs, with the exception of several accessory sex organs. Most human malignancies, 
regardless of the origins of the tissues, contain two major characteristics: uncontrolled growth 
and the ability to metastasize. Abnormalities of the same signaling pathways can be found in 
multiple types of human cancers; a tumor may contain multiple abnormalities in signaling. 
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Overlapping these abnormalities among multiple types of tumors may shed light on some key 
alterations in carcinogenesis.  
Prostate cancer is second only to skin cancer as the most commonly diagnosed malignancy 
in American men. Some studies suggested that up to 80% of men older than eighty were found to 
contain pathologically recognizable prostate cancer, while any man younger than forty rarely 
developed the same disease. This argues against any singular specific etiology responsible for 
prostate cancer besides aging. The clinical courses of most prostate cancers are long, and some 
are life-threatening. Hepatocellular carcinoma, on the other hand, is quite the opposite. It is not 
age related, and is tightly linked to cancer etiologies such as alcohol, the hepatitis B or C virus, 
and certain toxins. Hepatocellular carcinoma is distinctive in its well confined nodular 
architecture. The clinical courses of most of the hepatocellular carcinomas are short and the 
fatality is high. Most of the lung cancers, with the exception of small cell carcinoma, are also 
associated with distinctive etiologies, such as smoking or chronic exposure to certain type of 
carcinogens. The urothelial carcinoma of the urinary bladder, however, is primarily idiopathic or 
viral. Since these four types of cancer are so far apart in etiology, morphology and clinical 
courses, any common ground between these tumors could be interpreted as the likely common 
pathway of carcinogenesis.  
Microarray technology has been widely applied to the analysis of many malignancies, 
including the four cancer types mentioned in the literature above. However, using meta-analysis 
to integrate multiple studies has rarely been investigated. In this project, we performed a meta-
analysis on 455 arrays collected from four microarray studies in the Affymetrix U95Av2 
platform: 94 samples of liver tissue (Luo, et al. 2006), 148 samples of prostate tissues (Yu, et al. 
2004), 151 samples of lung tissues (Bhattacharjee, et al. 2001) and 62 urinary bladder tissues 
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(Stransky, et al. 2006). The liver and prostate samples contain three types of tissues: organ donor 
(N), adjacent to tumor (A) and tumor (T), while the lung and bladder samples only contain N and 
T. Detailed background introduction of this project is included in section 3.2.  
In section 3.3, the materials and methods used in our project will be described. We will 
focus on the filtering criteria for data preprocessing. We performed an analysis on two batches of 
samples. In batch I, all three tissue types in the liver and prostate samples were analyzed using 
the analysis of variance (ANOVA) model. In batch II, the normal and tumor tissues in all four 
cancer types were included and a t-test was used to identify predictive biomarkers. Gene-specific 
scaling is used in inter-cancer-type classification. Leave-one-out cross validation is conducted by 
PAM. Figure 3.3 describes this leave-one-out cross validation scheme. The prediction 
performance is measured by a confusion matrix and the prediction performance index (PPI), 
which is defined as the average of sensitivity and specificity. The gene ontology (GO) database 
was used for pathway enrichment analysis. Finally, a set of twenty-three external prostate cancer 
samples was used for external validation of the batchII-PBs. 
In section 3.4, the results section, we will show that the identified biomarkers have high 
predictability in both within-cancer-type (cross validation within a single cancer type) and inter-
cancer-type (i.e., a prediction model trained in one cancer type and used to predict another cancer 
type) prediction via leave-one-out cross validation. Further, pathway enrichment analysis 
identified statistically significant function categories of the biomarkers. Validation of the 47 
batch II predictive biomarkers on independent twenty-three prostate tissues yielded 96% 
accuracy in inter-study prediction from the original prostate, liver, and lung cancer data sets 
respectively, showing the robustness of the predictive biomarkers and their implications for 
common carcinogenesis of multiple cancer types.  
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In section 3.5, the forty-four batchI-PB genes will be investigated by their functions. We 
will discuss the two-fold clinical implication of our findings: therapeutic targeting toward some 
of these 44 genes will be of significant value in treating these malignancies since the prediction 
of liver, lung, and prostate cancer using our forty-four batchI-PBs is interchangeable.  Second, 
the ninety-nine batchII-PB model may be able to serve as a predictor of malignancies nearby 
even if a biopsy misses its tumor target. 
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2.1 ABSTRACT 
Motivation: Reproducibility of microarray experiments has been greatly improved in the past 
decade and its application in biomedical research is more and more prevalent. Independent 
studies investigating an identical disease with different array platforms and from different labs 
are often found in journals. Consistent high prediction accuracies are often reported in the 
individual studies; however, direct inter-study prediction by applying a prediction model 
established in one study to another usually generates poor performance. 
Results: We found that gene-specific discrepancies in the expression intensity levels across 
studies often exist even after proper sample-wise normalization, which cause a major difficulty 
in direct inter-study prediction. We proposed a ratio-adjusted sample-wise normalization 
followed by gene-wise normalization (SN+rGN) method to solve this problem. The proposed 
method significantly increased the prediction accuracies when such inter-study discrepancies 
existed in the predictive biomarkers. The ratio of sample sizes in normal versus diseased groups 
could affect the performance of gene-wise normalization and an analytical method was 
developed to adjust for the imbalanced ratio effect. Both simulation results and applications to 
three lung cancer and two prostate cancer data sets, considering both binary classification and 
survival risk predictions, showed significant and robust improvement of our method. A 
calibration scheme was developed to apply our method to prospective clinical trials. The number 
of calibration samples needed was estimated from existing studies and suggested for future 
applications. 
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2.2 INTRODUCTION 
Microarray technology has been widely used in biomedical research, for example, in prediction 
of cancer diagnosis (Golub, et al. 1999), of prognosis (van’t Veer, et al. 2002) and of treatment 
outcome (Shipp, et al. 2002) using supervised machine learning approaches. With an increasing 
amount of microarray data sets available, reproducibility analysis of these independent 
experiments has gained more attention and has been greatly improved in the past decade. Tan 
(2003) and his colleagues examined three microarray platforms and showed that the correlations 
of detected biomarkers were moderate to poor. This finding, together with other negative studies, 
stimulated more researchers to investigate improvement (Kuo, et al. 2006). Recently, the 
MicroArray Quality Control (MAQC) project was initiated to address this concern and they 
concluded that they found satisfying intra-platform consistency across test sites as well as a high 
level of inter-platform concordance in terms of genes identified as differentially expressed (DE) 
have been reached in most popular commercial platforms (Shi, et al. 2006). Yauk and Berndt 
(2007) reviewed these studies and concluded that with improvements in the technology (the 
optimization and standardization of methods, including data analysis) and annotation, analysis 
across platforms yields highly correlated and reproducible results. 
Most reproducibility studies in literature either compared and validated the DE genes or the 
biomarkers independently found in each study (Tan, et al. 2003; Shi et al.2006; Mitchell, et al. 
2004) or evaluated inter-lab or inter-platform concordance by correlation (Parmigiani, et al. 
2004). Direct application of prediction models to independent studies was, however, rarely 
investigated. For example, literature investigating lung cancer with different array platforms or in 
different labs is often reported with similar high disease prediction accuracies without mention of 
direct inter-study predictions (i.e., establishing a prediction model from one data set and applying 
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it another). This creates a barrier for the progress of array technology beyond bench work to 
prospective clinical use. Suppose a pilot study or clinical trial has performed in an old 
Affymetrix U95 platform and an effective prediction model has been constructed. The test site of 
another medical center may apply another commercial system (such as Agilent or Illumina 
platforms) or even the original medical center may migrate to a newer U133 system. The 
translational research of microarray would not be successful if the prediction model cannot 
predict inter-platform or inter-lab studies. This happens often because of the variety of 
microarray platforms. The major difficulties for such direct inter-study prediction may include: 
(1) biological differences in the sample population across studies (2) different sample 
preparations and experimental protocols and (3) different microarray platforms (Fishel, et al. 
2007). Different data preprocessing and incorrect gene matching across studies have also been 
mentioned to as having a great impact on such an inter-study analysis (Bosotti, 2007) and some 
practical guidelines have been suggested.  
Among the difficulties mentioned above, some can be overcome by applying consistent data 
preprocessing strategies or improving gene matching across studies. UniGene cluster ID has 
been commonly used as a gene identifier for gene matching (Parmigiani,  et al. 2004) , but it 
often happens that a gene can have multiple UniGene IDs, and many genes could share the same 
UniGene ID, which adds to the difficulty of gene matching. Entrez Gene ID turns out to be more 
unique and becomes more familiar to researchers (Bosotti, et al. 2007). In the other extreme, if 
the intrinsic difference across studies is indeed large due to a differential sample population or 
experimental protocols as mentioned in the first two points above, the direct inter-study 
prediction will never be valid. In this chapter of my dissertation, we investigate a commonly 
encountered situation – that the gene-specific discrepancies in the expression intensity levels 
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across studies are found even after proper sample-wise normalization. The gene-specific 
discrepancies often come from differential probe sequence selections and experimental protocols 
that caused different gene-specific hybridization efficiencies across studies. It is easily seen from 
the figure by Kuo et al (2006) which displayed the probe matching of various microarray 
platforms compared to the complete probe sequence within one exon of Gas1. Based on this 
figure (Figure 2.1 in this dissertation), the sequences of different platforms are quite different. 
An extreme example exists between Affymetrix and Academic cDNA where there is no 
overlapping at all.  In Figure 2.2A, for example, EMP2 is an ideal predictive biomarker that is 
down-expressed in the diseased group in the raw data (data with intra-study normalization but 
without inter-study normalization) of all three independent lung cancer studies (details of the 
data sets will be introduced later). The absolute intensities in the three studies are, however, at 
very different level. Direct applications of prediction models across studies using this biomarker 
will perform poorly in this case. For example, applying the prediction model from the Harvard 
study to the Michigan study will predict all subjects as cancer patients.  
 
Figure 2.1 Predictive biomarker with different expression intensity levels across studies 
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Figure 2.2 A predictive biomarker with different expression intensity levels across studies: 
Figure. 2.2A: raw data before any inter-study normalization. Figure 2.2B: inter-study sample-wise normalization 
with standard normalization(SN_std). Figure 2.2C: inter-study sample-wise normalization with median rank scores 
(SN_MRS). Figure 2.2D: inter-study sample-wise normalization and then gene-wise normalization with standard 
normalization ( SN_std+GN_std). H-: normal group for Harvard study. H+: tumor group for Harvard study. M: 
Michigan study; S: Stanford study. Means and error bars of expression intensities are represented on the y-axis. 
2.3 METHOD 
Inter-study normalization, which ensures the training data and the test data at a comparable 
expression level, is a critical step for direct inter-study prediction. Global sample-wise 
normalization methods such as standard normalization (standardizing each sample vector to zero 
mean and unit variance), Loess (Yang et al. 2002), rank invariant normalization (Tseng, et al. 
2001), and quantile normalization (Irizarry, 2003) are popular normalization methods for intra-
study normalization. They are usually effective to scale expression intensities of samples to a 
comparable level in a global genomic sense. Warnat et al. (2005) applied two intra-study sample-
wise normalization methods – median rank scores (MRS) and quantile discretizations (QD) – to 
an inter-study normalization of three pairs of Affymetrix versus cDNA microarray studies and 
concluded that the two sample-wise normalization methods facilitated successful inter-study 
prediction in two out of the three pairs of studies. Whether or when the sample-wise 
D.   SN_std
H- H+ M- M+ S- S
C.   SN_MR
H- H+ M- M+ S- S
B.   SN_std
H- H+ M- M+ S- S
A.   Raw
H- H+ M- M+ S- S
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normalization methods are applicable to other inter-study predictions was, however, not 
discussed. In Shabalin et al.’s (2008) approach, data from independent studies was sample 
standardized and gene median centered first,, and then was combine K-means clustering on both 
the column and row level for parameter estimation of the block liner model. The purpose of their 
study was to directly merge different data sets. They did not demonstrate the magnitude of 
improvement that the sophisticated clock linear model could provide in addition to simple 
sample standardization and gene median centering, and the selection of cluster size was 
somewhat arbitrary.  In Figures 2.2B and 2.2C standard normalization (std) and MRS are applied 
for inter-study sample-wise normalization. It is clearly seen that the expression levels of the gene 
EMP2 across studies are still not comparable and that the three pairs of direct inter-study 
prediction (Harvard vs Stanford, Stanford vs Michigan and Harvard vs Michigan) will fail with 
an average accuracy rate of 73% for std and 61% for MRS. In this paper, we proposed a sample-
wise normalization followed by gene-wise normalization as a necessary step for many inter-
study predictions to succeed. For example, in Figure 2.2D, the expression intensities after 
sample-wise and gene-wise normalization by simple standardization to zero mean and unit 
variance (SN_std+GN_std) will be scaled to a comparable range and an average accuracy of the 
three pairs of inter-study predictions can reach 94%, a magnitude similar to the accuracy level of 
a within-study cross validation accuracy. In this paper, we will examine properties of sample-
wise normalization followed by gene-wise normalization (SN+GN). We will demonstrate 
through simulation and real applications that the ratio between normal versus tumor samples 
affects the performance of gene-wise normalization. A ratio-adjusted gene-wise normalization 
method is thus proposed (SN+rGN). Through the remainder of this paper, we will denote the 
sample-wise normalization by SN, the gene-wise normalization by GN, and the ratio-adjusted 
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gene-wise normalization by rGN. Since rGN requires the knowledge of sample labels (normal or 
tumor) to calculate the sample-size ratio, it cannot be directly applied to a prospective clinical 
trial. To address this issue, we proposed a calibration scheme, which allocated a small number of 
samples with known classification labels in the new study as a calibration set for estimating the 
normalization factors across studies. The concept is similar to the common practice of 
performing a few test samples with known classification to calibrate an experimental instrument 
when it is installed in a new lab environment or when it is operated by a new technician. 
2.3.1 Data sets, preprocessing and gene matching 
Pair-wise inter-study predictions were performed on three lung cancer data sets, including 
normal and adenocardinoma samples from each study. Two of these studies, named Harvard 
(Bhattacharjee, et al., 2001) and Michigan (Beer, et al., 2002), used Affymetrix oligonucleotide 
arrays Hu95a and HG6800 respectively. The third one, named Stanford (Garber, et al., 2001), 
used the cDNA platform. The raw data of these three lung cancer studies were downloaded from 
the public internet domain (http://www.camda.duke.edu/camda03/datasets/).  Intra-study sample-
normalization for Harvard and Michigan was carried out in dChip using the invariant-set 
normalization. Standard normalization which standardizes each sample to zero mean and unit 
variance was applied to the cDNA data. Genes with low average intensities or small variability 
were filtered out based on the criteria developed in the original studies. Detailed information is 
listed in Table 2.1. 
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Table 2.1 Description of three lung cancer data sets 
 Harvard Michigan Stanford 
Array platform Affymetrix U95A 
Affymetrix  
HG6800 
cDNA 
# of samples 
(normal, adenocarcinoma) 
(17, 134) (10, 86) (5, 39) 
# of original transcripts 12,625 7,129 24,192 
# after filtering 4,861 5,119 4,123 
# with Entrez gene ID 4,756 5,053 3,774 
# after averaging probes with same EntrezID 4,107 4,467 3,399 
# of overlapping genes in pair-wise studies 
Harvard-Michigan: 2,493 
Harvard-Stanford: 1,493 
Michigan-Stanford: 1,594 
 
For gene matching across studies, Entrez IDs were used as the common identifiers. Several 
web-based gene annotation conversion tools are available, such as SOURCE (Diehn et al., 
2003), MatchMiner (Bussey and Sunshine, 2003), and DAVID (Dennis et al, 2003). In this 
paper, R package “annotate” was used to retrieve the Entrez IDs for the two Affymetrix data sets 
and MatchMiner was used for the cDNA data. Averaged values were taken for multiple probes 
sharing an identical Entrez ID. Table 2.1 provides detailed descriptions. There were 2,493 genes 
that overlapped in the Harvard and Michigan data set, 1,493 genes that overlapped in the 
Harvard and Stanford data sets and 1,594 genes that overlapped in the Michigan and Stanford 
data sets that were used for the analysis of direct inter-study prediction analysis in this paper. 
There were 81, 86 and 22 tumor samples respectively in the Harvard, Michigan and Stanford 
data sets with available survival follow-up information. These samples were used in the survival 
risk prediction analysis. 
The two prostate cancer sets, the Affymetrix U95a data: Welsh (Welsh et al., 2001) and 
cDNA data: Dhanasekaran (Dhanasekaran et al., 2001), were publicly available. The Welsh data 
set contains nine normal and twenty-five cancer samples while the Dhanasekaran has nineteen 
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and forteen respectively. Since these two data sets were pre-processed with only the Unigene ID 
provided, they were merged by Unigene ID. There were 3,078 genes left, which were the basis of 
the inter-study prediction analysis used in our project. 
2.3.2 Classification methods and evaluation 
To assess the performance of our proposed normalization method regarding binary classification 
(the prediction of normal versus cancer samples), we examined three popular classification 
methods in microarray analysis: Linear Discriminant Analysis (LDA), K-nearest neighbor 
(KNN), and Prediction Analysis of Microarrays (PAM). For ease of evaluation, comparisons of 
different normalization methods were performed with identical parameters (number of genes 
used in LDA, PAM and KNN) and the results were verified by varying parameters over a certain 
range.  
Overall prediction accuracy has been widely used as the evaluation index in many 
publications. It is, however, often a misleading measure, especially when the data set contains 
unbalanced sample sizes in groups. For example, the accuracy in the Michigan data set can be as 
high as 89.6% (86/96), even if the classification rule predicts all samples to be adenocarcinomas. 
A standard alternative to this situation may be the AUC (area under ROC curve) index by 
varying the classification threshold in the classification rule. This measure is, however, not 
readily available for classical methods like KNN. Even for methods that can calculate AUC, the 
measure is very unstable for small sample-size situations. In this paper, we applied a simple but 
robust prediction performance index (PPI) that is defined as the average of sensitivity and 
specificity of the prediction results. 
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To evaluate risk prediction of survival time, Supervised Principle Components (SuperPC) 
(Bair & Tibshirani, 2004) method was used to cross predict the survival risks of the three lung 
cancer data sets. The univariate Cox model coefficient fitting the expression intensities to the 
survival is calculated for each gene. The most significant fifty genes are kept and singular value 
decomposition (SVD) is applied to select the top three principal components for fitting the Cox 
linear model. The risk index is defined as the linear term in the Cox model and the median risk 
index value of all the training samples is used as the threshold for deciding high or low risk 
groups. Under this criterion, about half of the patients will be classified as the high risk group 
and the other half will be classified as the low risk group. Leave-one-out cross validation is used 
in the training set. We will perform cross validation for the risk prediction based on the training 
model.  The performance of risk prediction is determined by the separation of survival curves of 
high and low risk groups, which is often evaluated by the p-value and chi-square statistics of a 
log-rank test comparing the two Kaplan-Meier curves from predicted high and low risk groups.   
2.3.3 Ratio-adjusted gene-wise normalization  
Figure 2.2 shows that inter-study normalization is necessary before being able to perform inter-
study prediction (2. 2A) and sample-wise normalization across studies is not sufficient to correct 
the bias (Figure 2.2B and 2.2C). There are several potential reasons for such gene-specific 
intensity discrepancies. The major cause comes from different probe design in different array 
manufacturings. For example, the probes from Affymetrix GeneChip are short 25-mer oligos 
with multiple probes (11-16 probes) representing one gene. For cDNA microarrays, the probes 
are cDNA fragments that are usually hundreds of bases long. As a result, probes meant to 
measure an identical gene always have different target sequences for hybridization in different 
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platforms, which, in turn, introduces differential probe efficiency and affects the final intensity 
levels. Even if comparing studies of the same array platform, different sample preparations, as 
well as labelling and hybridization protocols, can possibly introduce such gene-specific intensity 
discrepancies. 
We proposed applying sample-wise standard normalization followed by gene-wise standard 
normalization (SN_std+GN_std) to alleviate the gene-specific discrepancies described above. 
Preprocessing by GN_std has been widely applied prior to gene clustering, to particular 
classification methods (SVM, KNN etc), and to dimension reduction (MDS and PCA) to obtain 
better scale invariant property. It is well-known that by performing GN_std, the Euclidian 
distance of two genes can be expressed by the correlation coefficient. Suppose ),...,(
11 nxxx =  
and ),...(
21 nyyy = are the expression values of two genes in a data set. The correlation 
coefficient and Euclidian distance are defined respectively as follows: 
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express the Euclidian distance as )),(1)(1(2),( yxrnyxd ′′−−=′′ . 
We observed that the ratios of normal and adenocarcinoma samples in the three lung cancer 
data sets were very close. Intuitively, GN_std is sensitive to the sample ratio between normal and 
diseased groups in a study. This motivated us to explore the role of the ratio played in GN_std. 
Simulation supports that GN_std is sensitive to the ratio imbalance of the training and test 
sample sizes. We proposed the following analytic approach for ratio adjustment by assuming an 
equal mixture in the paragraph below. 
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For a given gene g, we omit the subscript g and consider observed intensities 
),...,,...,(
21 11 nn
yyxx after sample-wise intra-study normalization, where the first 1n  samples are 
from the normal group and the next 2n  samples are from tumor patients. Suppose ),...,( 11 nxx  are 
i.i.d. from distribution X  and ),...(
21 n
yy are from Y  and ,)( XuXE =
2)( XXVar σ= , ,)( YuYE =  
2)( YYVar σ= . GN_std standardizes gene vector to a mean of 0 and a standard deviation of 1 by 
stdGN
stdGNistdGN
i b
ax
x
_
_)_( −=  and 
stdGN
stdGNistdGN
i b
ay
y
_
_)_( −= ,  
where )(1)(1ˆ 21
2121
_ YXiistdGN ununnn
yx
nn
a ⋅+⋅
+
≈∑ ∑+
+
=  (1) 
and 
))()((
1
1ˆ 2_
2
_
21
2
_ ∑ −+∑ −−+
= stdGNistdGNistdGN ayaxnn
b
))()((
1
1 2
21
2
2121
∑
+
∑ ∑+−+∑
+
∑ ∑+−
−+
=
nn
yxy
nn
yxx
nn
ii
i
ii
i  
))()((
1
1 2
2122
2
211121 nn
yx
n
y
n
yy
nn
yx
n
x
n
xx
nn
iiii
i
iiii
i +
∑ ∑+−∑+∑−∑+
+
∑ ∑+−∑+∑−∑
−+
=
2
211
2
121
)()((
1
1
∑ ∑
+
∑ ∑+−∑+∑−
−+
=
nn
yx
n
x
n
xx
nn
iiii
i  
                            ))()(
2
212
2
2
∑ ∑
+
∑ ∑+−∑+∑−+
nn
yx
n
y
n
yy iiiii  
2
211
11212
1
21
)
)(
()1((
1
1
∑
+⋅
∑ ∑ ∑ ∑⋅−⋅−⋅+⋅+⋅−
−+
≈
nnn
ynxnxnxnn
nn
iiii
Xσ  
                     ))
)(
()1( 2
212
22212
2 ∑ +⋅
∑ ∑ ∑ ∑⋅−⋅−⋅+⋅+⋅−
nnn
ynxnynynn iiiiYσ  
 24 
))
)(
()1()
)(
()1((
1
1 2
212
21212
2
2
211
21212
1
21
∑
+⋅
⋅⋅−⋅⋅
+⋅−∑ +
+⋅
⋅⋅−⋅⋅
+⋅−
−+
≈
nnn
unnunnn
nnn
unnunnn
nn
XY
Y
YX
X σσ
))(
)(
)1()(
)(
)1((
1
1 2
2
21
2
12
2
2
2
21
2
22
1
21
∑ −⋅
+
+⋅−∑ +−⋅
+
+⋅−
−+
= yxYyxX uu
nn
nnuu
nn
nn
nn
σσ
1
)()1()1(
21
2
21
212
2
2
1
−+
−
+
⋅
+⋅−+⋅−
=
nn
uu
nn
nnnn yxYX σσ
 
 
It is clearly seen that results of GN_std greatly depend on the sample sizes 1n  and 2n . We 
propose below a ratio-adjusted gene-wise normalization (rGN_std). The empirical distribution 
obtained from ),...,(
11 n
xx and ),...(
21 n
yy  are denoted by X ′ and Y ′ . In other words, the cdf of 
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two ratio-adjusted scaling parameters are invariant to n1 and n2. 
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This analytic approach for ratio-adjustment could be easily extended when there are more 
than two groups in the data. Suppose K groups are available, we can generate Z’ to be the 
mixture of all the groups with equal weight: 
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2.3.4 Simulation  
We performed simulations under two scenarios to examine the effects of the sample ratio on 
normal and diseased groups in the performance of gene-wise normalization for prediction. In 
scenario one, the ratios in the training and test set are equal (1:1), while the ratios are opposite in 
scenario two: 3:1 in the training and 1:3 in the test set.  In scenario one, we simulated a ratio-
balanced univariate gene scenario for the training data and for the test data. Expression 
intensities for 100 normal samples were simulated from N(3.5, 1) and 100 tumor samples were 
simulated from N(6.5, 1). In the test data, we assumed that the hybridization efficiency was 
doubled and the expression intensities of 100 normal samples were simulated from N(7, 22) and 
100 tumors were simulated from N(13, 22). In scenario two, a ratio-imbalance scenario, the 
distributions remained the same but training data contain 150 normal and 50 tumor samples 
while test data contained 50 normal and 150 tumor samples. A univariate (one marker) 
prediction model was constructed from the training data using linear discriminant analysis 
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(LDA) and then was evaluated in the test data. The simulation was performed 1,000 times and 
the average error rate was reported. The performance of no GN (raw data), GN_std, rGN_std and 
the optimal Bayes error rate are evaluated. The Bayes error rates based on the Bayes optimal 
classifier given the underlying simulation model were calculated for both scenarios. Specifically  
∫∫ <> ⋅+⋅= λλ t YYt XXyxBayes dttfPdttfPPPYXError )()(),,,(  if E(X)<E(Y) and λ is the solution to 
)()( λλ YYXX fPfP ⋅=⋅ . In scenario 1, PX=PY=0.5; in scenario 2, PX=0.25 and PY=0.75. 
2.3.5 Calibration scheme for perspective studies 
SN_std+rGN_std cannot be applied directly to a test data set if the sample labels are unknown. In 
order to estimate the stdGNa _ and 
2
_ stdGNb  for each gene in the test data in a prospective study, 
a small data set including both normal and disease samples are needed to serve as calibration 
sample. Figure 2.3 describes a calibration scheme for applying the proposed SN+rGN method to 
construct a prediction model from an existing training study and to perform prediction in a 
prospective test study.  SN_std+rGN_std is performed in the training study and a classification 
model is obtained. In the prospective test study, a small set of calibration samples with known 
disease labels is available and SN_std+rGN_std is similarly applied to estimate the normalization 
factors. Finally, the normalization factors obtained from the calibration set and the classification 
model obtained from the training study are applied to all prospective test samples to generate the 
final prediction.  
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Figure 2.3 A calibration scheme for prospective study 
2.4 RESULTS 
2.4.1 Simulations to validate ratio-adjusted procedure 
The raw and normalized data from simulation under both scenarios are displayed in Figure 2.4. 
By comparing Figures 2.4C and 2.4D, GN_std normalization result in near optimal prediction 
under scenario 1, but not under scenario 2. The ratio-imbalanced situation was corrected by 
rGN_std (Figure 2.4F). Table 2.2 lists the mean error rate of constructing a prediction model 
from the training data and predicting the test data (by LDA) using raw data, and data after 
applying either the GN_std or rGN_std methods based on 1,000 simulations. The optimal Bayes 
errors based on the simulation distribution assumptions were calculated for reference. In scenario 
1, the error rates of applying GN_std and rGN_std are identical and very close to the Bayes error 
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rate. In scenario 2, GN_std does not perform well due to imbalanced sample ratios and applying 
rGN_std greatly improves GN_std. 
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Figure 2.4 Raw Prediction in raw and normalized data from simulation 
Figure 2.4A (scenerio1, raw data), Figure 2.4B (scenerio2, raw data), Figure 2.4C (scenerio1, GN_std), Figure 2.4D 
(scenerio2, GN_std), Figure 2.4E (scenerio1, rGN_std), Figure 2.4F (scenerio2, rGN_std), 
Solid dots: normal samples, circles: tumor samples 
Solid horizontal line: prediction threshold from the training set, used to predict the test set 
 
Table 2.2  Mean error rate of 1,000 simulations 
Error rate Training => Test Scenario 1 Scenario 2 
Raw 42.0% 21.0% 
GN_std 6.7% 37.5% 
rGN_std 6.7% 6.6% 
Bayes error 6.7% 5.5% 
 29 
2.4.2 Inter-study prediction regarding binary classification 
We compared inter-study performance using Raw, as well as data normalized by the following 
methods: SN_std, SN_std+GN_std, and SN_std+rGN_std to three lung cancer data sets: 
Harvard, Michigan and Stanford. The with-in study prediction in each individual study had 
nearly perfect performance in either SN_Std or SN_std+GN_std, confirming previous reports. 
We tested three prediction methods: PAM, LDA and KNN. The results were slightly different 
but similar and we only report PAM results here. The results by LDA and KNN are presented in 
the Appendix A. Figure 2.5 shows the PPIs of all three pair-wise inter-study predictions with 5, 
10, 50, 100, 200 and 500 genes used in the training set. The lines 1, 2, 3, and 4 stand for raw 
data, SN_std,  SN_std+GN_std, and SN_std+rGN_std respectively. Without any inter-study 
normalization (Raw), all the inter-study predictions performed poorly with PPIs around 50%, 
which is a result of almost all the samples being predicted into one group (similar to the 
univariate situation in Figure 2.2A). SN_std dramatically improved the inter-platform prediction 
between Harvard and Michigan, two Affymetrix data sets (Figure 2.5A and 2.5B). It also 
improved when predicting Stanford study (Figures 2.5C and 2.5E) but not using Stanford to 
predict the other two studies ( Figures 2.5D and 2.5F). Overall, SN_std+GN_std improved 
SN_std and the results after applying SN_std+rGN_std performed the best for inter-study 
prediction. For example, in Figure 3F, SN_std+rGN_std was the only normalization method 
which produced good inter-study prediction. 
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Figure 2.5  Inter-study prediction of lung cancer data by PAM 
We performed the same comparison for two prostate cancer studies: Welsh and 
Dhanasekaran (Figure 2.6). Inter-study predictions based on the raw data had the worst 
performance and all the normalization methods provided some improvement. Overall, 
SN_std+rGN_std has the best prediction accuracy rate and it achieves a 100% accuracy rate 
when the Dhanasekaran study is used as training data to predict the Welsh study, shown by line 4 
in Figure 2.6B. 
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Figure 2.6 Inter-study prediction of prostate cancer data by PAM 
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Following the calibration scheme described in Figure 2.3, we randomly selected a few samples 
from the test set to as use a calibration to perform SN_std+rGN_std for inter-study prediction of 
the three lung cancer studies. Similarly, we only report the results by PAM here, while the results 
by LDA and KNN are presented in Appendix A. The numbers of the samples in the calibration 
are 1:1 (1 normal and 1 adenocarcinoma), 2:2, and 3:3 shown by line 1, 2, and 3 in Figure 2.7 
respectively. The prediction results were based on an average of ten random draws of calibration 
samples. In general, larger numbers of calibration samples provide better estimate of 
normalization factors. The improvement from 1:1 to 2:2 was significant while not much 
improvement was gained from 2:2 to 3:3. Most of the three pair-wise cross predictions have PPIs 
above 70%, and line 2 and 3 have PPIs above 90% most of the time. Line 1 with only 2 samples 
has the worst results when compared to lines 2 and 3. The result provides a practical guideline 
that a calibration set of three normal samples and three tumor samples should be used when 
designing a prospective clinical trial in an independent medical center or using a different array 
platform. 
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Figure 2.7  Inter-study predictions by SN_std+rGN_std with different number of 
calibration samples 
2.4.3 Inter-study prediction regarding survival risk 
 
Figure 2.8 shows the within-study prediction results (with leave-one-out cross-validation) based 
on a processed data set without inter-study gene-matching. We omitted the prediction based on 
the raw data because it performed poorly. The with-study predictions after SN_std are displayed 
on the left and the with-study predictions after SN_std+GN_std are displayed on the right side of 
Figure 2.8. In general, prediction results from SN-std+GN_std performed better than SN_std 
only in that the log-rank test p-values were more significant and the numbers of predicted high-
risk and low-risk samples were more balanced, which is expected since the median threshold 
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from the training data was used. For example, the log-rank test p-value of the Michigan study 
improved from 0.38 to 0 in Figure 2.8C and 2.8D. The predicted risk group sizes were sixty-two 
and twenty-four after applying SN_std and became more balanced (forty-four and forty-two) 
after SN_std+GN-std.  
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Figure 2.8 Within-study survival prediction 
Figure 2.8A: Within-study prediction in the Harvard study after SN_std ,based on 50 genes.  Figure 2.8B: Within-
study prediction in the Harvard study after SN_std+GN_std, based on 50 genes. 
 
Figure 2.9 shows pair-wise inter-study prediction for all three lung cancer studies comparing 
SN_std and SN_std+Gn_std.  As Figure 2.8 shows as well, inter-study predictions after SN_std 
are displayed on the left and inter-study predictions after SN_std+GN_std are displayed on the 
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right. The only improvement happened in Michigan versus Stanford. Similar to the results in 
Figure 2.8, SN_std produced confusing results (Figures 2.9I and 2.9K), where samples predicted 
as low-risk had worse survival rates than the high-risk group. Results from SN_std+GN_std 
(Figures 2.9J and 2.9L), corrected the error and provided more reasonable predictions. Although 
there was no obvious improvement from SN_std to SN_std+GN_std in Harvard versus Michigan 
and Harvard versus Stanford, we still noticed some differences.  First, the numbers of samples 
predicted in the low and high risk groups are more even for SN_std+GN_std than SN_std. For 
example, the numbers are seventy-two and nine (Figure 2.9C) and they became forty-one and 
forty (Figure 2.9D). Also, in Figure 2.9G, the prediction model built on the Stanford study could 
not distinguish the between high risk and low risk in the Harvard samples, and all of the eight-
one Harvard samples were predicted to be in the low risk group after SN_std; in Figure 2.9H, 
after applying additional GN_std, twenty-one samples were predicted as low risk and sixty 
samples were predicted as high risk. 
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Figure 2.9 Inter-study survival prediction 
Figure 2.9A: Prediction of the Michigan study after SN_std, using the Harvard model. 
Figure 2.9B: Prediction of the Michigan study  after SN_std+GN_std, using the Harvard model. 
Figure 2.9C: Prediction of the Harvard study after SN_std, using the Michigan model. 
Figure 2.9D: Prediction of the Harvard study after SN_std+GN_std, using the Michigan model. 
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2.5 DISCUSSION 
2.5.1 Gene-wise Normalization (GN) 
Sample-wise normalization (SN) is a routine step in supervised machine learning for microarray 
data and it works well in many within-study cases, thus GN_std is seldom discussed in the 
literature. However, GN could be a critical factor when dramatic differences exist between 
different platforms and none of the SN methods is expected to bring the expression values to the 
same level for all genes. As we have shown in this study, implementation of GN is fast and a 
significant improvement is often obtained compared to SN only. We suggest that GN should be 
applied in the analyses to directly carry prediction models from one study to another. However, 
GN should be applied cautiously because it is sensitive to the ratio of disease groups in the 
training and test set. 
2.5.2 Applicability of calibration  
Calibration of experimental instruments is a common and necessary practice when installed in a 
new lab or operated by a new technician. It is especially necessary when preparing for a large 
survey or screen test. Our proposed SN_std+rGN_std method requires knowledge of sample 
labels in the test set for proper gene-wise normalization. As a result, a calibration scheme was 
developed for application to a real prospective clinical trial. In our analysis of the three lung 
cancer data sets, a small calibration set of three normal and three diseased samples was 
sufficient. Although experimental quality and genetic variation may be different in other 
diseases, it provides a rough guideline for real life applications. 
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2.5.3 Application in survival analysis by SuperPC 
To further investigate the cause of improvement in GN, we conducted a Principle Component 
Analysis (PCA) on the three individual lung cancer data sets based on the top 50 genes, 
comparing normalization by SN_std and SN_std+GN_std. It is clearly shown in Figure 2.10 that 
the PCA is heavily dominated by the first component after applying SN_std for all three studies. 
By additional GN_std, proportions of information after the second principal component are 
increased and can be better utilized to construct the prediction model. This explains why 
additional GN improves the prediction performance. 
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Figure 2.10 PCA based on unmatched data 
In the SN_std+GN_std normalization for the survival analysis of these three lung cancer 
data sets, we did not adjust for the ratio because the prediction of survival risk, in some sense, is 
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not a supervised analysis, unlike the prediction of disease classification. Furthermore, because all 
of the samples in the training and test set are tumor samples, the difference between the low-risk 
and high-risk groups is much smaller than the one between the normal samples and the tumor 
samples. The sample ratio issue is not as critical here. In general, predicting survival is more 
difficult than predicting disease classification, and we only observed obvious improvement of 
SN_std+GN_std over SN_std in the inter-study prediction between Michigan and Stanford. 
However, we did observe the importance and necessity of performing GN_std based on the 
within-study leave-one-out cross validation in Figure 2.8.  
2.5.4 Clinical implication 
As we mentioned in the introduction, studies performing direct inter-study prediction of 
microarrays are rare, especially when the training and the test studies are from different 
microarray platforms due to all kinds of technical difficulties. Suppose we need to do cross-
prediction of a prospective microarray study from a certain platform. It could not be successfully 
accomplished if no prior study from the same platform exists, which happens often because of 
the variety of microarray platforms. Even for a platform like Affymetrix, the probe designs have 
been changed gradually and extensively. In reality, in order to predict a prospective study, we 
usually need to have a training study from the same platform as the test study, which is not 
always available. By applying our proposed SN+GN normalization method, together with an 
appropriate data preprocessing strategy and gene matching, we can cross-predict the prospective 
study using training set in any platform most of the time. On the other hand, for a certain disease, 
if there is a microarray study of a very good data quality, such as good completeness, a large 
enough sample size, and a high self-prediction accuracy, we can trust this study and use it to 
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predict possibly any study. Also, with more and more microarray studies available, there is an 
urgent need to combine the information from all the studies. Our proposed normalization method 
makes that possible. 
2.5.5 Limitations 
This study performed inter-study analyses for the same disease and showed that with appropriate 
normalization method, high prediction accuracy could be obtained. However, if the analyses are 
conducted between different organs or different diseases, such as the liver and prostate cancer 
data, it is highly possible that some genes could never be brought to the same level between 
training and test data sets due to the intrinsic differences even with SN+GN. Also, when few 
similar significant genes exist across the studies, cross prediction could be very difficult and 
SN+GN cannot solve it.  As we see from the survival prediction between Harvard and Michigan, 
and Harvard and Stanford, the additional GN after SN is not better, although neither is it worse. 
Last, when the calibration data is not available or not reliable, the rGN cannot be accomplished. 
2.6 CONCLUSIONS 
In this study, we investigated the normalization issue for enhancing inter-study disease 
prediction, a critical issue for microarray translational research. Instead of developing more 
sophisticated sample-wise normalization methods (SN), we observed that gene-wise 
discrepancies of expression levels across studies are often significant in impeding successful 
inter-study prediction and that gene-wise normalization (GN) is necessary. We further found that 
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differential sample size ratios of diseased and normal groups greatly deteriorate the gene-wise 
standardization procedure. An analytical method with equal mixture assumption was proposed 
for ratio-adjusted gene-wise normalization (rGN). Finally, since the sample labels are needed to 
perform rGN, we developed a practical calibration scheme for the design of a prospective 
clinical trial. 
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3.1 ABSTRACT 
Microarray technology has been widely applied to the analysis of many malignancies, however, 
integrative analyses across multiple studies are rarely investigated. In this study we performed a 
meta-analysis on the expression profiles of four published studies analyzing organ donor, benign 
tissues adjacent to tumor and tumor tissues from liver, prostate, lung and bladder samples. We 
identified 99 distinct predictive biomarkers in the comparison of all three tissues in liver and 
prostate and 44 in the comparison of normal versus tumor in liver, prostate and lung. The bladder 
samples appeared to have a different list of predictive biomarkers from the other three cancer 
types. The identified predictive biomarkers achieved high accuracy similar to using whole 
genome in the within-cancer-type prediction. They also performed superior than the one using 
whole genome in inter-cancer-type prediction. To test the validity of the predictive biomarkers, 
23 independent prostate cancer samples were evaluated and 96% accuracy was achieved in inter-
study prediction from the original prostate, liver and lung cancer data sets respectively. The 
result suggests that the compact lists of predictive biomarkers are important in cancer 
development and represent the common signatures of malignancies of multiple cancer types. 
Pathway analysis revealed important tumorogenesis functional categories. 
3.2 INTRODUCTION 
Human malignancies can occur in almost all organs, with the exception of several accessory sex 
organs. Most human malignancies, regardless of the origins the of tissues, contain two major 
characteristics: uncontrolled growth and the ability to metastasize. Abnormalities of the same 
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signaling pathways can be found in multiple types of human cancers; a tumor may contain 
multiple abnormalities in signaling. Overlapping these abnormalities among multiple types of 
tumors may shed light on some key alterations in carcinogenesis.  
Prostate cancer is second only to skin cancer as the most commonly diagnosed malignancy 
in American men: at current rates of diagnosis, one man in six will be diagnosed with the disease 
during his lifetime (Jemal, et al. 2005). Even though nutritional and environmental etiology has 
been implicated for prostate cancer development, such link has yet to be firmly established in 
general population. Some studies suggested that up to 80% of men older than 80 were found to 
contain pathologically recognizable prostate cancer, while men below 40 rarely developed the 
disease. This argues against any singular specific etiology responsible for prostate cancer besides 
aging. Histologically, prostate cancer cells closely interact with their neighbor stromal cells to 
form some distinctive architectural patterns that make up the basis of Gleason’s grading 
(Gleason 1966). The clinical courses of most prostate cancers are long, and some are life-
threatening. Hepatocellular carcinoma, on the other hand, is quite the opposite. It is not age 
related, and is tightly linked to cancer etiologies such as alcohol, the hepatitis B or C virus and 
certain toxins. Hepatocellular carcinoma is distinctive in its well confined nodular architecture. 
The clinical course of most of the hepatocellular carcinomas are short and the fatality is high. 
Most of the lung cancers, with the exception of small cell carcinoma, are also associated with 
distinctive etiologies, such as smoking or chronic exposure to certain type of carcinogens. The 
urothelial carcinoma of the urinary bladder, however, is primarily idiopathic or virus related. 
Since these four types of cancers are so far apart in etiology, morphology, and clinical courses, 
any common ground between these tumors could be interpreted as the likely common pathway of 
carcinogenesis.  
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Microarray technology has been widely applied to the analysis of many malignancies, 
including the four cancer types mentioned in the literature above. However, using meta-analysis 
to integrate multiple studies has rarely been investigated. Segel et al (Segal, et al. 2004) 
proposed a systematic approach to incorporate 1,975 arrays in 22 tumor types and constructed a 
large gene module map. The resulting module map was, however, too complex to follow up and 
the modules were based on 2,849 known biologically meaningful gene sets instead of learning 
new sets of predictive biomarkers. The gene matching of heterogeneous array types also 
potentially deteriorate the analysis accuracy. In this report, we performed a meta-analysis on 455 
arrays collected from four microarray studies in Affymetrix U95Av2 platform: 94 samples of 
liver tissue (Luo, et al. 2006) (43 liver cancer, 30 hepatic tissues adjacent to liver cancer, 21 
normal liver from organ donors), 148 samples of prostate tissues (Yu, et al. 2004) (66 prostate 
cancer, 59 prostate tissues adjacent to prostate cancer and 23 organ donors), 151 samples of lung 
tissues (Bhattacharjee, et al. 2001) (134 tumors and 17 normal lung tissues) and 62 urinary 
bladder tissues (Stransky, et al. 2006) (5 normal and 57 tumors). The use of common array 
platform has avoided the problem of incorrect gene matching and gene annotation, a common 
cause to deteriorate the performance of meta-analysis in microarray (Kuo, et al. 2006). We 
performed an analysis on two batches of samples. In batch I, all three tissue types in the liver and 
prostate samples were analyzed using the analysis of variance (ANOVA) model. In batch II, the 
normal and tumor tissues in all four cancer types were included and a t-test was used to identify 
predictive biomarkers (see Table 3.1 for data description). The identified biomarkers were found 
to have high predictability in both within-cancer-type (cross-validation within a single cancer 
type) and inter-cancer-type (i.e. a prediction model trained in one cancer type and used to predict 
another cancer type) prediction via leave-one-out cross validation. Further pathway enrichment 
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analysis identified statistically significant function categories of the biomarkers. Validation of 
the 47 batch II predictive biomarkers on 23 prostate tissues yielded 96% accuracy in inter-study 
prediction from the original prostate, liver and lung cancer data sets respectively, showing the 
robustness of the predictive biomarkers and their implications to common carcinogenesis of 
multiple cancer types.  
Table 3.1  Overview of data sets used in batch I and batch II analyses. 
Batch I Analysis 
 Organ Donor (N) 
Adjacent 
to Tumor (A) 
Tumor 
(T) Total 
Liver 21 30 43 94 
Prostate 23 59 66 148 
Batch II Analysis 
 Organ Donor (N) Tumor (T) Total 
Liver 21 43 64 
Prostate 23 66 89 
Lung 17 134 151 
Bladder 5 57 62 
3.3 MATERIALS AND METHODS 
3.3.1 Data and preprocessing  
We collected four published microarray data sets (Bhattacharjee, et al. 2001; Luo, et al. 2006; 
Stransky, et al. 2006; Yu, et al. 2004) to perform meta-analysis on prostate, liver, lung and 
bladder samples. A total of 455 U95Av2 arrays were analyzed (94 liver, 148 prostate, 151 lung 
and 62 bladder tissues) with each covering 12,625 genes and EST sequences. The common array 
platform eliminated technical difficulties including gene matching and inter-platform 
discrepancies. In liver and prostate data sets, three types of samples were collected: organ donor 
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(N), normal tissues adjacent to tumor (A) and tumor tissues (T). In lung and bladder tissues, only 
organ donor and tumor tissues were available. We analyzed the data through two batches of 
analyses. In the first batch, both liver and prostate data sets with all three tissues were included. 
The expression patterns across the three types of samples were the major targets for 
investigation. In the second batch, data of all four organ types were included and only normal 
and tumor samples were compared. For details see Table 3.1. 
The raw data (CEL files) were preprocessed in each cancer type separately using dChip 
software for array quality assessment, normalization, expression intensity extraction and log-
transformation (base 2). Genes of low information content in each data set were filtered 
respectively and the union gene set of the four data sets was retrieved for further analysis. 
Specifically, in each data set, the top 50% genes with the largest average intensities were first 
selected. Among them the top 50% genes with the largest standard deviations were further 
identified, resulting in 25% genes (3,156 genes) selected in each data set. The union list of these 
most informative 25% genes in four data sets was used for subsequent downstream analysis (a 
total of 5,917 genes). 
3.3.2 Biomarker selection by ANOVA and t-test 
 In batch I analysis, ANOVA model was fitted for the organ donor (N), adjacent to tumor (A) 
and tumor (T) samples with a β  parameter for field effect and a γ  parameter for tumor effect. 
Stepwise algorithm was used to select the best regression model. The ANOVA model is 
described in the following: 
ininiiniiin TFY εγβα +⋅+⋅+=  
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where i =1,… 5917 for all the genes, n =1,… 94 for liver samples and n=1,… 148 for 
prostate samples. The field effect binary covariate Fin = 1 for A or T group; Fin = 0 for N group. 
The tumor effect covariate Tin = 1 for T group; Tin = 0 for N or T group. Field effect is defined as 
the expression difference between normal tissues (N) compared to tissues adjacent to tumor (A) 
and tumor tissue (T). Tumor effect is defined as a further difference between A and T. Genes 
satisfying the following criteria were selected: (a) statistical significance: adjusted q-value for the 
final stepwise-selected ANOVA model after Benjamini-Hochberg correction is less than 0.05 
(i.e. to control false discovery rate smaller than 0.05); (b) biological significance: field effect or 
tumor effect is larger than 0.4 (correspond to ~32% fold change). The field effect and tumor 
effect parameter β  and γ  both have three possibilities-- positive, negative and no change --, 
resulting in eight patterns as described in Figure 3.1A. Figure 3.1B and 3.1C shows the number 
of genes selected in liver and prostate samples respectively and their distribution in the eight 
pattern categories. The intersection of selected ANOVA genes in liver and prostate with 
concordant pattern categories were used to construct prediction model for within-cancer-type 
(Liv→Liv and Pro→Pro) and inter-cancer-type (Liv→Pro and Pro→Liv) analysis. To 
summarize a list of gene markers in batch I for further analysis, genes selected in more than 70% 
of the times in leave-one-out cross validation (see section below for more detail) in the above 
procedure were identified as the “batch I predictive biomarkers” (batchI-PBs). 
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Figure 3.1 ANOVA model for batch I analysis 
 (A) Eight categories of ANOVA patterns used to select predictive biomarkers. N denotes 
normal, A tissue adjacent to cancer, and T tumor sample. (B) Venn diagram representation 
of the number of ANOVA genes found to be significantly altered in liver and prostate 
tissues when comparing N, A and T groups. (C) Bar graph of genes that were altered in 
liver (1854), prostate (1139) or both tissue samples with same pattern (111). (D) Histogram 
of correlations of N-A-T patterns across prostate and liver of the 520 common ANOVA 
genes. 
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 In the batch II analysis, similar gene selection procedure was performed. Instead of 
ANOVA, simple t-test was performed to distinguish normal and tumor. Given the comparison of 
a pair of cancer types (e.g. liver vs lung), genes satisfying the two criteria used in batch I were 
first selected and the intersection of the gene lists obtained from the two compared cancer types 
were identified. Among them, genes with concordant differential expression direction (up- or 
down-regulation) were used to construct prediction model for within-cancer-type (Liv→Liv and 
Lun→Lun) and inter-cancer-type (Liv→Lun and Lun→Liv) analysis. Leave-one-out cross 
validation was similarly performed. For each pair of cancer type comparison, gene lists of more 
than 70% appearance in the leave-one-out cross validation signatures were identified and were 
denoted as “liv-pro-PBs” (i.e. predictive biomarkers in liver-prostate comparison), “liv-lun-PBs” 
etc. The intersection genes of “liv-pro-PBs”, “liv-lun-PBs” and “pro-lun-PBs” are denoted as 
“batchII-PBs” (See Figure 3.5; bladder cancer data appear to be very different from liver, 
prostate and lung as will be describe later). 
3.3.3 Gene-specific scaling in inter-cancer-type classification  
Figure 3.2 demonstrates expression patterns of one selected gene for each of the eight pattern 
categories (the category (N=T)>A had no gene and is omitted). We observed that gene-specific 
scaling was needed for many of the biomarkers so the prediction information could be carried 
across organs. For example in “APBA2BP”, the expression of group A is consistently greater 
than N and group T is further greater than A in both liver and prostate samples. However, the 
levels of expression intensities in liver and prostate are in different scale even though all the liver 
and prostate samples are preprocessed and properly normalized across data sets. This 
phenomenon may be due to differential sample preparation, tissue physiology and/or 
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hybridization conditions in different studies. As a result, we conducted gene-specific scaling in 
all inter-cancer-type classification. Conceptually the scaling parameters are estimated so that the 
gene vectors in each study are standardized to mean 0 and standard deviation 1. However, since 
each study has a different ratio of normal versus tumor samples, we performed a bootstrap 
sampling before scaling so that the gene vectors were standardized under a synthetic condition 
that groups (N, A and T) are of equal sample size in each study (see Appendix for more details). 
 
Figure 3.2 Expression patterns of selected representative genes in liver and prostate samples. 
Selected genes of seven pattern categories from the 111 common concordant ANOVA genes in liver and prostate 
samples. Global sample normalization has been performed across prostate and liver data sets. It is clearly seen that 
although all these biomarkers demonstrate  concordant patterns across prostate and liver, many of them (APBA2BP, 
SLC39A14, AGT, TOP2A and B2M) are at different expression level and direct application of a prediction model 
developed in one data set will likely perform poor in the other data set. 
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3.3.4 Classification method and leave-one-out cross validation  
PAM (Prediction Analysis of Microarrays) was used to construct the prediction models in this 
paper (Tibshirani, et al. 2002). The method has been found effective in many microarray 
prediction analyses and has the merit that gene selection is embedded in the method. When “all 
genes” are used, the predictive genes are automatically chosen from the total of 5,917 genes to 
construct the prediction model. When “common signatures” are used, the common biomarkers 
are selected according to the description in the section “Biomarker selection by ANOVA and t-
test” and no gene selection is further performed in PAM. Results of both gene selection 
procedures are reported and compared. To avoid over-fitting in the evaluation of cross-
predictability of the predictive biomarkers, we conducted rigorous leave-one-out cross validation 
(see the prediction scheme in Figure 3.3A and 3.3B), i.e. the left out sample does not participate 
in the selection of marker genes. 
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Figure 3.3  Schemes of leave-one-cross-validation or external validation for batchI-PBs and 
batchII-PBs.  
Upper: scheme for leave-one-out cross validation to evaluate the procedure of selecting batchI-PBs and batchII-PBs. 
The test sample is first left aside. The remaining samples are used for selecting predictive biomarkers and construct 
the prediction model to be used to evaluate the set-aside test sample. This scheme is used to evaluate procedures of 
selecting both batchI-PBs and batchII-PBs to generate Table 3.2 and Table 3.3. (A) an example to evaluate liv→liv 
in Table 3.2 (B) an example to evaluate pro→liv in Table 3.2. Lower: scheme for external validation of batchII-PBs 
by 23 independent prostate cancer samples. (C) external evaluation of the prediction model based on liver data and 
batchII-PBs (EV_liv→pro). (D) external evaluation of the prediction model based on the old prostate data and 
batchII-PBs (EV_pro→pro). 
 
3.3.5 Confusion matrix and prediction index  
In the literature, the overall accuracies from different methods are usually reported to compare 
performance. It is, however, often a misleading index in practice. Supplementary Table B.1 
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demonstrates an example. Among 42 tumor patients, one false negative was made and among six 
normal patients, five false positives were made. The overall accuracy is pretty high (87.5 %) but 
it is a result of predicting almost all tissues as tumor with high sensitivity (97.6%) but extremely 
low specificity (16.7%). To solve this problem, reporting both sensitivity and specificity or 
plotting the receiver operating characteristic (ROC) curve is commonly used. In this paper, we 
report the confusion matrixes that convey the entire prediction results in the appendix. A 2×2 
table is used to summarize the number of patients in true and predicted status of normal or tumor 
groups. The two off-diagonal numbers represent the false positives and false negatives in the 
prediction and their sum represent to total errors made (see Supplement Table B.1). We then 
further summarize the prediction results by a prediction performance index (PPI) that is defined 
as the average of sensitivity and specificity, to be used throughout this paper for performance 
evaluation. 
3.3.6 Pathway analysis  
For each gene list of predictive biomarkers, the gene ontology (GO) database was used for 
pathway enrichment analysis. For each GO term, a Fisher’s exact test was performed to 
determine the enrichment of the gene list and a p-value was generated (Draghici, et al. 2003). 
We performed this analysis in batchI-PBs, batchII-PBs and all pairwise comparison predictive 
biomarkers in batch II (liv-pro-PBs, liv-lun-pro-PBs etc). The p-value results were summarized 
in a heatmap (Figure 3.4). 
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Figure 3.4  Pathway analysis heatmap. 
The enriched Gene Ontology terms are demonstrated on rows and lists of predictive biomarkers are shown on 
columns. The significance (p-values) is represented by gradient red color. 
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3.3.7 External evaluation of batchII-PBs by independent prostate data  
A data set of 23 prostate cancer samples independently performed by LaTulippe et al. 
(LaTulippe, et al. 2002) was used for external validation of the batchII-PBs. A toltal of 47 
batchII-PBs were identified from the normal and tumor samples in liver, prostate and lung data 
sets. To evaluate the robustness and inter-cancer-type cross-predictability, a prediction model 
based on the 47 batchII-PBs in the normal and tumor samples of liver data set was constructed 
and was used to evaluate the 23 external prostate cancer samples (see “EV_liv→pro in Figure 
3.3C). The evaluation of prediction model generated by the old prostate data is denoted by 
“EV_pro→pro” in Figure 3.3D. Similarly we also perform “EV_lun→pro” evaluation. The data 
preprocessing of the 23 new samples was conducted similarly to the four analyzed data sets and 
simple constant normalization was adopted against the original prostate data set. Additional 
gene-wise normalization against the original prostate is also applied so the liver and lung data 
sets can be used to predict the 23 new prostate samples. 
3.4 RESULT 
To identify common signature genes among four types of malignancies, we started with the 
prostate and liver data sets in batch I analysis because of more balanced numbers of tumor and 
normal samples and availability of benign tissues adjacent to tumor. In this analysis, 1,854 genes 
from liver data set and 1,139 genes from the prostate data set were found to fit the ANOVA 
model and meet the gene selection criteria. Among these genes, 520 genes were common in both 
organs (Venn diagram in Figure 3.1B). The histogram of correlations of N vs A vs T patterns 
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(average intensities of each group) across two organs in each gene is shown in Figure 3.1D. 
Majority of the genes were highly correlated across prostate and liver but surprisingly 113 genes 
presented strong negative correlation (<-0.7), which may reflect the differences in tissue types. 
The 520 selected genes were categorized into eight patterns as demonstrated in Figure 3.1A. 
These patterns represent either tumor specific alteration, field effect, or reactive changes. Among 
these 520 genes, 111 genes were in the same pattern categories in liver and prostate (Figure 
3.1C) based on our definition in Figure 3.1A. Further analysis of expression of the 111 genes in 
both organs indicated that even though the expression patterns for these genes across N, A and T 
were identical in both organs, the levels of expressions may vary greatly (for example, 
APBA2BP and SLC39A14 in Figure 3.2). This suggests that direct application of classification 
model constructed in one cancer type may not predict the histology of tissues in the other cancer 
type. To resolve this problem, an adequate gene-specific scaling across organs was carried out 
for the inter-cancer-type prediction. The gene-specific scaling procedure described in the Method 
section and Appendix is applied for all analyses hereafter. 
We performed leave-one-out cross validation throughout the prediction analyses. There are 
242 samples in liver and prostate data sets. Among the 242 leave-one-out cross validation 
analysis, a total of 109 common biomarkers were identified in more than 70% leave-one-out 
cross validation and all of them belong to the 111 gene list using all liver and prostate samples 
described above. These 109 frequently identified  biomarkers are named “batchI-PBs”. 99 (out of 
109) were identified as distinct predictive biomarkers (Supplement Table B.4). Subsequently we 
assessed the cross-predictability of the identified biomarkers. When using all genes, we observed 
high PPI between normal and tumor comparison (N vs T) with 96.5% in liver dataset and 93.9% 
prostate dataset while lower accuracy was observed between adjacent and tumor (79.9% in liver 
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and 71.4% in prostate) (Table 3.2). When only common signature biomarkers were used, the 
prediction accuracy remained comparable to using all genes (N vs T: 96.5% in liver and 98.8% 
in prostate; A vs T: 75.6% in liver and 66.7% in prostate). The result suggests that the common 
signature biomarkers carry as good predictive information as the entire 5,917 genes. We then 
further conducted inter-cancer-type classification analysis. We used either “all genes” (the entire 
5,917 genes) or the common signatures to construct a prediction model in one cancer type and 
predict in another cancer type. The prediction evaluation was performed in a manner of leave-
one-out cross validation. We denoted “prostate→liver” as constructing prediction models using 
prostate samples and predicting liver samples. We found that prediction with “all genes” did not 
perform well with only 47.4% in liver→prostate and 66.3% in prostate→liver among N vs T 
comparison and 55.7% in liver→prostate and 51.9% in prostate→liver among A vs T 
comparison. On the other hand, the model using common signature genes achieved much 
superior performance, nearly as good as the within-cancer-type classification (96.3% in 
liver→prostate and 93% in prostate→liver among N vs T comparison and 65.1% in 
liver→prostate and 74.7% in prostate→liver among A vs T comparison). The results clearly 
demonstrate the cross-predictability of the common signatures.  
Table 3.2  Prediction performance indexes (PPI) in batch I analysis 
Liver vs Prostate (Normal vs Tumor) 
   liv→liv pro→liv pro→pro liv→pro 
All genes 96.5% 66.3% 93.9% 47.4% 
Common 
signature 96.5% 93.0% 98.8% 96.3% 
Liver vs Prostate (Normal vs Adjacent) 
   liv→liv pro→liv pro→pro liv→pro 
All genes 92.6% 77.9% 96.6% 54.6% 
Common 
signature 98.2% 96.0% 98.3% 96.6% 
Liver vs Prostate (Adjacent vs Tumor) 
   liv→liv pro→liv pro→pro liv→pro 
All genes 79.9% 51.9% 71.4% 55.7% 
Common 
signature 75.6% 74.7% 66.7% 65.1% 
        Pairwise two-group comparisons (N vs T, N vs A and A vs T) are performed. 
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  Table 3.3  Prediction performance indexes (PPI) in batch II analysis. 
Liver vs Prostate  
 liv→liv pro→liv pro→pro liv→pro 
All genes 96.51% 66.28% 93.94% 47.36% 
Common 
signature 97.67% 97.67% 95.55% 94.14% 
Liver vs Lung 
 liv→liv lun→liv lun→lun liv→lun 
All genes 96.51% 56.98% 90.72% 45.32% 
Common 
signature 95.23% 93.02% 95.94% 94.72% 
Lung vs Prostate 
 lun→lun pro→lun pro→pro lun→pro 
All genes 90.72% 69.03% 93.94% 62.88% 
Common 
signature 94.82% 94.45% 79.61% 72.76% 
Liver vs Bladder 
 liv→liv bla→liv bla→bla liv→bla 
All genes 96.51% 62.79% 88.60% 49.65% 
Common 
signature 91.74% 91.86% 98.25% 98.25% 
Prostate vs Bladder 
 pro→pro bla→pro bla→bla pro→bla 
All genes 93.94% 36.30% 88.60% 42.63% 
Common 
signature 92.92% 86.86% 97.81% 88.25% 
Lung vs Bladder 
 lun→lun bla→lun bla→bla lun→bla 
All genes 90.72% 51.87% 88.60% 50.88% 
Common 
signature 89.38% 85.91% 97.37% 85.61% 
 
Table 3.4  PPI summary of within-cancer-type and inter-cancer-type predictions in batch II 
analysis.  
  test data 
  Liver Prostate Lung Bladder 
tr
ai
ni
ng
 
da
ta
 Liver 96.5% (69)* 94.1% (225)
 + 94.7% (119) + 98.3% (53) + 
Prostate 97.7% (225)+ 93.9% (55)* 94.5% (288) + 88.3% (10) + 
Lung 93.0% (119) + 72.8% (288) + 90.7% (57)* 85.6% (19) + 
Bladder 91.9% (53) + 86.9% (10) + 85.9% (19) + 88.6% (135)* 
*: All genes are used in the within-cancer-type prediction to allow PAM for automatic 
predictive gene selection. Numbers of genes used in PAM are shown in parentheses. 
+: In all inter-cancer-type predictions, only common signature genes are used in PAM and 
PAM does not perform further gene selection. The numbers of genes appeared more than 
70% of leave-one-out cross validations are shown in the parentheses (i.e. liv-pro-PBs, liv-
lun-PBs and pro-lun-PBs). 
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Table 3.5  The 44 batchII-PBs overlapped by pair-wise comparisons of liver, prostate and lung 
data sets.   
Probe Set ID Gene Title Gene Symbol 
39597_at* actin binding LIM protein family, member 3 ABLIM3 
37599_at* aldehyde oxidase 1 AOX1 
34736_at* cyclin B1 CCNB1 
37302_at* centromere protein F, 350/400ka (mitosin) CENPF 
37203_at* carboxylesterase 1 (monocyte/macrophage serine esterase 1) CES1 
32168_s_at* Down syndrome critical region gene 1 DSCR1 
34311_at* glutaredoxin (thioltransferase) GLRX 
1737_s_at* insulin-like growth factor binding protein 4 IGFBP4 
609_f_at* metallothionein 1B MT1B 
36130_f_at* metallothionein 1E MT1E 
31622_f_at* metallothionein 1F MT1F 
39594_f_at* metallothionein 1H MT1H 
35699_at BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) BUB1B 
38796_at complement component 1, q subcomponent, B chain C1QB 
35276_at claudin 4 CLDN4 
36668_at cytochrome b5 reductase 3 CYB5R3 
33295_at Duffy blood group, chemokine receptor DARC 
41225_at dual specificity phosphatase 3 (vaccinia virus phosphatase VH1-related) DUSP3 
38052_at coagulation factor XIII, A1 polypeptide F13A1 
37743_at fasciculation and elongation protein zeta 1 (zygin I) FEZ1 
38326_at G0/G1switch 2 G0S2 
1597_at growth arrest-specific 6 GAS6 
411_i_at interferon induced transmembrane protein 2 (1-8D) IFITM2 
37484_at integrin, alpha 1 ITGA1 
38116_at KIAA0101 KIAA0101 
37883_i_at Hypothetical gene supported by AK096951 LOC400879 
242_at microtubule-associated protein 4 MAP4 
31623_f_at metallothionein 1A MT1A 
39081_at metallothionein 2A MT2A 
37736_at protein-L-isoaspartate (D-aspartate) O-methyltransferase PCMT1 
35752_s_at protein S (alpha) PROS1 
34163_g_at RNA binding protein with multiple splicing RBPMS 
34887_at radixin RDX 
39150_at ring finger protein 11 RNF11 
41096_at S100 calcium binding protein A8 S100A8 
33443_at serine incorporator 1 SERINC1 
39775_at 
serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, 
hereditary) 
SERPING1 
1798_at solute carrier family 39 (zinc transporter), member 6 SLC39A6 
33131_at SRY (sex determining region Y)-box 4 SOX4 
40419_at stomatin STOM 
1897_at transforming growth factor, beta receptor III TGFBR3 
38404_at 
transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase) 
TGM2 
40145_at topoisomerase (DNA) II alpha 170kDa TOP2A 
35720_at WD repeat domain 47 WDR47 
The first 12 genes with asterisk overlapped batchI-PBs. 
 60 
Subsequently, we expanded our analysis to prostate, lung, liver and bladder data sets (batch 
II analysis) with only normal and tumor tissues to test whether common signature genes can be 
found across these four types of cancers. Similar analyses were performed except that ANOVA 
was replaced by t-test for two class normal and tumor comparison. Each pair of the cancer types 
was analyzed. Similar to batch I analysis, only common signature genes with consistent 
regulation direction (up-regulation or down-regulation) in both cancer types were selected. Table 
3.3 (see also Supplement Table B.3 for the entire confusion matrix results) summarizes the 
prediction results of batch II analysis. Similar to the result of batch I analysis, we observed high 
prediction accuracy for within-cancer-type prediction when using all genes in PAM (96.5% for 
liver, 93.9% for prostate, 90.7% for lung and 88.6% for bladder). The prediction models using 
common signature biomarkers generated similar high accuracy compared to using all genes 
(91.7%-97.7% in liver, 79.6%-95.6% in prostate, 89.4%-96.0% in lung and 97.4%-98.3% in 
bladder). The result confirms that the common signature biomarkers carry as good predictive 
information as the entire 5,917 genes. For the inter-cancer-type classification analysis, we 
repeatedly found that prediction with all genes did not perform well. In contrast, using common 
signature genes achieved much superior performance (Table 3.4). Liver particularly seemed to be 
the most robust either used as training or test data. Bladder, however, showed slightly lower 
cross-predictability with the other three cancer types. The numbers of common signature genes 
of bladder with other cancer types are also much smaller. Following the same criterion of 
selecting 70% frequency of being selected as common signatures in the cross-validations, we 
identified predictive biomarkers of the comparison in each pair of cancer types in Table 3.4 (255 
liv-pro-PBs, 119 liv-lun-PBs, 288 lun-pro-PBs, 53 liv-bla-PBs, 10 pro-bla-PBs and 19 lun-bla-
PBs). When all possible pairs of comparisons among liver, prostate and lung are overlapped (liv-
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pro-lun-PBs), a number of 47 genes was identified. After deleting replicates, 44 (out of 47) 
distinct predictive biomarkers in liver, prostate and lung cancers were identified as batchII-PBs 
(Table 3.5). However, these common signature genes do not overlap with those from bladder 
data set, indicating a lack of common signature between these cancers and bladder cancer. There 
are 12 overlapping genes (Figure 3.5; p<1E-10 with significantly high overlapping) between 
batchI-PBs and batchII-PBs (marked with asterisk in Table 3.5 and Supplement Table B.4). 
Pathway analysis was performed on these predictive biomarkers indicating that fewer numbers of 
predictive biomarkers and GO terms were identified when bladder samples were analyzed in the 
inter-cancer-type prediction.  
 
Figure 3.5  Diagram of batchI-PBs and batchII-PBs and their intersection genes. 
The 47 batchII-PBs are listed in Table 3.5 and 109 batchII-PBs are listed in Supplement Table B.4. 
 
To validate the robustness and cross-predictability of batchII-PBs, a data set of 23 
independent prostate cancer samples obtained from another institute (LaTulippe, et al. 2002) was 
evaluated. The prediction model based on the 47 batchII-PBs in the 64 normal and tumor liver 
 62 
samples achieved 96% (22/23) accuracy in predicting the 23 independent prostate samples (the 
“EV_liv→pro” scheme in Figure 3.3C). Evaluation of “EV_pro→pro” and “EV_lun→pro” also 
gave the same results (96% accuracy). Since we only have tumor samples in the external prostate 
data, there is a potential pitfall that the high accuracy may be an accidental result of study 
discrepancies between the new 23 prostate samples and the normal and tumor samples in 
analyzed data sets. We performed multi-dimension scaling (MDS) plots to visualize the new and 
old samples and excluded this possibility (Figure 3.6). The new prostate tumor samples are 
scattered and mixed with the old tumors but separated from old normal samples. As a result, the 
high accuracy of the prediction on this new data set is not caused by pure “accident”. 
 Figure 3.6  MDS plot of existing training data set and independent prostate cancer data.  
Three MDS plots of the existing liver, prostate and lung training data sets respectively with the 23 independent 
prostate tumor samples. The mixing of the 23 tumor samples and old tumor samples exclude the possibility of 
accidental high accuracy due to study differences. 
3.5 DISCUSSION 
Meta-analyses had been performed for several types of human malignancies (Best, et al. 2003; 
Mehra, et al. 2005; Ramaswamy, et al. 2003; Rhodes, et al. 2002; Rubin, et al. 2004; Warnat, et 
al. 2005). However, to our knowledge, this is the first report showing that a microarray gene 
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expression model demonstrates inter-cancer predictability between different types of cancers 
using the identified predictive biomarkers. These results not only were evaluated in cross-
validation analysis of existing working data sets but also were validated by independent prostate 
tissues collected and preprocessed separately. This argues strongly in favor of the reproducibility 
of the predictive biomarkers and the models. The 44 batchII-PBs appear to represent the 
common gene expression alteration among hepatocellular carcinoma, lung  and prostate cancer. 
They follow similar patterns of differential expression in normal and tumor tissues for prostate, 
lung and liver cancer. Surprisingly, these gene signatures predict prostate, lung and 
hepatocellular carcinoma with similarly high accuracy as using the entire genome information of 
5917 genes in each within-cancer-type prediction in prostate, lung or liver cancer. This suggests 
that the 44 genes are the major determinant of gene expression alteration in these three types of 
cancers.  
The high level of inter-organ cancer predictability using just 44 genes implies that the core 
of cancer gene alterations may actually be quite small. The alterations of the expression of these 
genes could represent the common features of the three types of malignancies. None of these 
genes was, however, identified as the most significantly altered in bladder cancer suggest the dis-
resemblance of bladder cancer to these three types of cancers. Among these genes includes a 
interferon inducible protein, 1-8D (IFITM2, 411_i_at). This gene was a known important 
mediator of interferon induced in cell growth inhibition and induction of cell death (Deblandre, 
et al. 1995; Lewin, et al. 1991). 1-8D was down-regulated in hepatocellular carcinoma, lung 
cancer and prostate cancer, while pro-growth genes such as cyclin B1 (CCNB1, 34736_at) was 
significantly up-regulated in three types of tumor samples. Other genes involving in growth 
controls including growth arrest specific 6 (GAS6, 1597_at), G0/G1swtich 2 (GOS2, 38326_at) 
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are also abnormally expressed in these tumors. The 44 gene list also includes six 
metallothioneins including 1A, 1B, 1E, 1F, 1H and 2A (MT1A, 31623_f_at; MT1B, 609_f_at; 
MT1E, 36130_f_at; MT1F, 31622_f_at; MT1H, 39594_f_at; MT2A, 39081_at). 
Metallothioneins are some low molecular weight zinc binding proteins that play important role in 
regulating transcriptional activity for variety of genes, and play crucial role in zinc signaling 
(Foster, et al. 1988; Tsuji, et al. 1992). Abnormal up-regulation of these genes may result in 
global pattern of gene expression alteration. Up-regulation of metallothioneins were thought to 
contain prognostic value in invasive ductal breast cancer (Schmid, et al. 1993). CCNB1 and most 
of the metallothioneins were also identified in batchI-PBs where adjacent tissues were included 
in the analysis. In the pathway analysis, we also observe many cancer related functional 
categories, including “mitotic checkpoint”, “apoptotic program”, “copper ion binding” and 
“cadmium binding”.  Investigation into the abnormalities of these pathways may yield important 
insight into the common carcinogenesis mechanism of the tumors. 
The clinical implication of our finding is two-fold: If the prediction of hepatocellular 
carcinoma, lung cancer and prostate cancer using our 44 batchI-PBs is interchangeable, we like 
to hypothesize that the abnormalities in the expression of the 44 genes represent a common 
features of these malignancies. Therapeutic targeting toward some of these genes will be of 
significant value in treating these malignancies. Second, the 99 batchII-PBs predicts tissues 
adjacent to malignancies versus completely normal organ tissues with high accuracy. This model 
may be able to serve as a predictor of malignancies nearby even if a biopsy misses its tumor 
target.  This may serve as an indicator for a quick follow-up re-biopsy until the tumor(s) is 
identified. Alternatively, the detection of a strong cancer field effect change may argue for some 
prophylactic treatments before morphological cancer appears.   
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4.0  CONCLUSION, DISCUSSION AND FUTURE WORK 
The microarray technology has been proven useful in the biomedical field. The analysis of 
multiple microarray studies faces many challenges. My dissertation treats the statistical analyses 
of multiple microarray studies. 
Literature investigating the same disease with different array platforms or in different labs is 
often reported with similar high disease prediction accuracies without mention of direct inter-
study predictions. In section 2.2, we described the many technical difficulties that exist for direct 
application of prediction models to independent studies. Inter-study normalization is a critical 
step for inter-study prediction, especially when data sets are from different platforms. The first 
part of this dissertation aims to develop an improved and robust normalization method for the 
inter-study prediction. Our proposed method yielded better inter-study prediction results and the 
improvement is more obvious for inter-platform prediction. 
In the literature, multiple microarray studies for the same disease are very common. 
However, meta-analysis to integrate multiple studies has rarely been investigated. Inter-study 
prediction for better disease diagnosis and information integration for better biomarker detection 
are important issues to enhance the clinical utility of microarray. Therefore, our other goal is to 
detect the common predictive biomarkers in the microarray studies of four different cancer types. 
Based on the gene list we identified, high cross prediction accuracy was achieved. Although we 
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have talked about the conclusions and discussions in each chapter, we will summarize it and 
demonstrate our future works based on what we have found in this dissertation. 
4.1 RATIO-ADJUSTED GENE-WISE NORMALIZATION 
4.1.1 Conclusion 
We draw the following conclusions from the ratio-adjustment gene-wise normalization project: 
most of the time, sample-wise normalization is helpful, but is not enough in inter-study 
prediction, especially for inter-platform prediction. Thus we turn to gene-wise normalization. 
The sample size ratio of different disease groups in one study has influence on the gene-wise 
normalization. Our proposed method, SN_std+rGN_std with calibration had accurate and robust 
results in the inter-study and inter-platform prediction. GN can also be used in analyses 
involving principle components analysis. 
4.1.2 Discussion 
In section 2.5, we focused our discussions on our proposed normalization method, particularly on 
its strength, application, and limitations. Here, we will discuss two issues in a bigger scope, the 
inter-study and inter-platform prediction. 
First, one important issue regarding inter-study analysis is gene-matching. From Table 2.1, 
we see the number of overlapping genes between the two Affymetrix sets: Harvard and Michigan 
have 2,494 out of over 4,000 overlapping genes in each unmatched study. There are only around 
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1,500 genes remaining after merging between Affymetrix and cDNA sets. Therefore, we lose 
more than half of the information for the inter-study analysis. Even for these overlapping genes, 
some of those expression intensities are quite different due to the probe designs as well as other 
protocol problems as we introduced in section 2.2. Even worse, some genes could have opposite 
expression patterns across disease groups in different studies, which makes it more difficult to 
build a powerful and compact prediction model. As we see from Figures 2.5, 2.6, and 2.7, the 
PPI increases as more genes are used in the training set.  Furthermore, this big model cannot be 
used to predict a third study directly due to the gene-matching problem. A metagene  (i.e. a linear 
weighting of expression intensities of all genes) approach which captures the major, invariant 
biological features and reduces noise has often been used by researchers to combine and to 
compare different microarray studies (Shen, et al 2004; Pittman et al, 2004; Tamayo et al 2007). 
However, this approach still cannot resolve the gene-matching problem. In other words, if only 
one element of the metagene - a single gene - is missing in the test set, this approach will not 
work.  
 Second, our proposed method, SN_std+GN_std outperforms SN_st in the inter-study 
prediction of the first two examples with binary outcome. For the survival prediction of the three 
lung cancer data sets, we only observed obvious improvement in one of the three pairs shown by 
Figure 2.9. However, the significant improvement exists in all three within-study leave-one-out 
predictions shown in Figure 2.8.  We also observed that the sample sizes of the two risk groups 
after SN_std+GN_std are more even as they are supposed to be. Although we explained it 
through the PCA data in section 2.5.3, there are still some questions that remain unanswered. For 
example, how can the inter-study survival prediction be improved? How important is the ratio of 
 68 
sample size in true low and high risk groups? How can our proposed method be extended to 
studies involving Principle Component Analysis (PCA)? 
4.1.3 Future work 
In the first part of the above discussions, we listed a few problems for gene-based inter-study 
prediction and while the metagene approach is popular and useful, it has its weaknesses. An 
ongoing project of Zhibao Mi, one of our group members, is performing methodological 
exploration on module-based prediction. This project is being conducted under the guidance of 
Dr. George Tseng, and I have participated in this project as well. This approach does not require 
complete gene matching and is robust to the existence of non-matched genes across studies. The 
cross prediction is based on the modules generated by the clustering method on the entire 
genome before merging. For example, if a module in the training set consists of ten genes, it will 
work as long as at least one of these ten genes exists in the test set to form the corresponding 
module. Our proposed method, SN_std+rGN_std is used for inter-study and inter-platform 
normalization. In the future, I will work on two aspects of this project: 1) cluster size estimation 
on various level of gene overlapping and 2) comparison of gene-based approaches with module-
based approach. 
For the second issue in section 4.1.2 concerning survival prediction, we plan to do further 
research on the three lung cancer data sets. Regarding the improvement of within-study survival 
prediction, we will first pull out the top 50 genes selected for SuperPC, and then investigate each 
of them for their contribution and influence in the Principle Component Analysis (PCA). We will 
repeat and compare this for raw data, for example,data after applying SN_std and 
SN_std+GN_std. We will find out which genes dominate the PCA without additional GN_std 
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and see how these genes behave in the survival analysis. We will work on improving the inter-
study prediction if it is possible. At last, we will employ more examples for the prediction of 
prognosis, such as these three famous publicly available breast cancer data sets: Sorlie(2001), 
VanDeVijver(2002) and Huang(2003). 
4.2 COMMON PREDICTIVE BIOMARKERS IN MULTIPLE CANCER TYPES 
4.2.1 Conclusion 
The identified common predictive biomarkers achieved high accuracy similar to using whole 
genomes in the within-cancer-type and inter-cancer-type prediction. They also performed 
superior to the method using the whole genome in inter-cancer-type prediction. Compact lists of 
predictive biomarkers are important in cancer development and represent the common signatures 
of malignancies of multiple cancer types.  
4.2.2 Discussion 
This project is more focused on the interpretation of the detected common biomarkers from the 
microarray data of four cancer types. Although we did not apply sophisticated statistical 
methods, the result serves as a starting point for information integration of such multi-class data 
sets. We performed an ANOVA analysis on the liver and prostate cancer sets in batch I 
individually, and a t-test was used for the analysis of batch II. Next, we selected the significant 
genes by certain criteria and merged them to get the common predictive biomarkers. Because all 
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the studies are from the same Affymetrix chip, there are not as many technical difficulties as we 
encountered in the first project. Strictly speaking, it is not a traditional meta-analysis. It would be 
better if we analyze the data again by more rigorous statistical meta-analysis methods. For 
example, Fisher’s (1932) equal weight approach uses the test statistic involving the log-
transformation of p-values to Chi-square scores. Tippett’s (1931) approach uses the minimum p-
value instead.  
 
4.2.3 Future work 
One of our group members, Jia Li, under the supervision of Dr. George Tseng, compared most of 
the current meta-analysis methods regarding detection of differently expressed (DE) genes. They 
illustrated two statistical hypothesis settings and proposed an optimally weighted statistic and a 
maximum p-value statistic for the two questions, respectively. Permutation analysis was then 
applied to control the false discovery rate (FDR). They further showed the advantage of their 
proposed test procedures over existing methods by power comparison, simulation study and real 
data analyses of a multiple-tissue energy metabolism mouse model data sets and prostate cancer 
data sets. In the future, we will adopt their approach to reanalyze the four cancer data sets. We 
will compare the results of their method with the results we got from our simple method 
regarding the gene list and prediction accuracy. 
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APPENDIX A: SUPPLEMENT MATERIAL OF CHAPTER 2 
A. 1 CROSS PREDICTION FIGURES FOR LUNG CANCER DATA 
LDA was used for all pair-wise cross prediction for the three lung cancer data sets. Figure A.1 
display the prediction results comparing raw data and data after three normalization approaches: 
SN_std, SN_std+GN_std and SN_std+rGN_std. As we know, the number of genes in the training 
model of LDA cannot exceed the number of samples; thus we varied the gene numbers from 5 to 
30. The prediction results are not stable based on these genes. Contradicting genes which have 
different expression patterns across studies could be selected in the training model and those 
genes may destroy the cross prediction severely. This phenomenon happens more often in the 
inter-platform scenario than the intra-platform scenario. This is why we observed a dramatic 
decrease of prediction accuracy in subfigures D, E and F in Figure A.1. Overall, line 4 
(SN_std+rGN_std) has the best prediction performance. 
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Figure A.1  Inter-study prediction by LDA 
Figure A.2 shows the inter-study prediction results by KNN with K fixed at 5 and the 
number of genes in the training model varying from 5 to 500 like the prediction by PAM. KNN 
has very similar performance to PAM as shown in Figure 2.5. For the cross prediction between 
the Harvard and Michigan studies, except for in the raw data, all three normalization approaches 
achieve good cross-predictions. In the inter-platform prediction, line 4 (SN_std+rGN_std) 
outperforms the other two normalization methods and yields very accurate and stable prediction 
performance. As we observed from Figure A.2F, line 4 has PPIs over 80% all the time, while 
line 1, line 2, and line 3 completely failed with the prediction. 
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Figure A.2  Inter-study prediction by KNN 
Figures A.3 and A.4 show the inter-study predictions of three lung cancer data sets by 
applying the normalization method: SN_std+rGN_std with calibration using prediction tools 
LDA and KNN respectively.  Both methods require at least two normal and two adencarcinoma 
samples for calibration and both yield satisfactory normalization.  
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Figure A.3  Inter-study prediction applying SN_std+rGN_std with calibration by LDA 
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Figure A.4  Inter-study prediction applying SN_std+rGN_std with calibration by KNN 
A. 2 CROSS PREDICTION FIGURES FOR PROSTATE CANCER DATA 
Figure A.5 and A.6 show the inter-study prediction of two prostate cancer data sets 
comparing raw data and data after three normalization approaches: SN_std, SN_std+GN_std and 
SN_std+rGN_std using LDA and KNN respectively.  Similar to the lung cancer studies, the 
LDA method is not as stable as PAM and KNN. Also, line 4 (SN_std+rGN_std) has the best 
performance for both methods. 
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Figure A.5 Inter-study prediction of two prostate studies by LDA 
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Figure A.6  Inter-study prediction of two prostate studies by KNN 
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APPENDIX B: SUPPLEMENT MATERIAL OF CHAPTER 3 
B. 1 BOOTSTRAP PROCEDURE FOR GENE-WISE NORMALIZATION 
Conceptually we standardize each gene vector to mean 0 and standard deviation 1 to 
accommodate different expression range of a predictive biomarker across different studies (e.g. 
APBA2BP, SLC39A14, AGT, TOP2A and B2M in Figure 3.2). Since the ratios of normal and 
tumor groups can vary in different studies, simple standardization can cause bias and deteriorate 
the prediction performance. Instead we perform bootstrap to sample a gene vector of B=1,000 
samples in each group and standardize the vector of 2,000 (3,000 if N, A and T groups are all 
compared) bootstrapped samples to mean 0 and standard deviation 1 to estimate the 
standardization factors. Essentially we perform standardization under the simulated condition 
that normal and tumor groups have the same sample sizes. 
Table B.1  An example of confusion matrix. 
 true normal tissues true tumor tissues 
predicted as normal tissues 1 1 
predicted as tumor tissues 5 41 
Two false negatives and five false positive are made in the prediction, which sum up to seven total errors (with 
42/48=87.5% overall accuracy). The sensitivity is 41/42=97.6%, specificity 1/6=16.7% and prediction performance 
index (PPI) (97.6%+16.7%)/2 =57.2%. 
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Table B.2  Batch I leave-one-out cross validation analysis result (confusion matrix) 
Liver vs Prostate (Normal vs Tumor) 
   liver→liver prostate→liver   prostate→prostate liver→prostate 
   True N True T True N True T   True N True T True N True T 
All genes 69 Predicted N 21 3 21 29 55 Predicted N 23 8 19 58 Predicted T 0 40 0 14 Predicted T 0 58 4 8 
Common  
signature 111.3 
Predicted N 21 3 20 4 111.9 Predicted N 23 1.6 22 2 Predicted T 0 40 1 39 Predicted T 0 64.4 1 64 
Liver vs Prostate (Normal vs Adjacent) 
   liver→liver prostate→liver   prostate→prostate liver→prostate 
   True N True A True N True A   True N True A True N True A 
All genes 66 Predicted N 20 3 18 9 63 Predicted N 23 4 15 33 Predicted A 1 27 3 21 Predicted A 0 55 8 26 
Common  
signature 111.2 
Predicted N 21 1.1 20 1 110.4 Predicted N 23 2 23 4 Predicted A 0 28.9 1 29 Predicted A 0 57 0 55 
Liver vs Prostate (Adjacent vs Tumor) 
   liver→liver prostate→liver   prostate→prostate liver→prostate 
   True A True T True A True T   True A True T True A True T 
All genes 64 Predicted A 27 13 13 17 266 Predicted A 44 21 46 44 Predicted T 3 30 17 26 Predicted T 15 45 13 22 
Common  
signature 111.5 
Predicted A 27 16.7 26 16 112.0 Predicted A 42 25 41 26 Predicted T 3 26.3 4 27 Predicted T 17 41 18 40 
*The numbers marked in dark gray are the number of genes used to construct the prediction model. When “all 
genes” are used, the PAM method performs automatic gene selection to construct the model. When “common signature 
genes” are used, no gene selection is performed in PAM and the results (number of genes and confusion matrix) shown 
are averages of leave-one-out cross-validation results. 
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Table B.3  A Batch II leave-one-out cross validation analysis result (confusion matrix) 
Liver vs Prostate 
   liver→liver prostate→liver   prostate→prostate liver→prostate 
   True N True T True N True T   True N True T True N True T 
All genes 69 Predicted N 21 3 21 29 55 Predicted N 23 8 19 58 Predicted T 0 40 0 14 Predicted T 0 58 4 8 
Common  
signature 225.9 
Predicted N 21 2 21 2 222.0 Predicted N 21.3 1 21 2 Predicted T 0 41 0 41 Predicted T 1.7 65 2 64 
Liver vs Lung 
   liver→liver lung→liver   lung→lung liver→lung 
   True N True T True N True T   True N True T True N True T 
All genes 69 Predicted N 21 3 21 37 57 Predicted N 16 17 13 115 Predicted T 0 40 0 6 Predicted T 1 117 4 19 
Common  
signature 120.1 
Predicted N 21 4.1 21 6 120.3 Predicted N 16 3 16 6 Predicted T 0 38.9 0 37 Predicted T 1 131 1 128 
Lung vs Prostate 
   lung→lung prostate→lung   prostate→prostate lung→prostate 
   True N True T True N True T   True N True T True N True T 
All genes 57 Predicted N 16 17 17 83 55 Predicted N 23 8 23 49 Predicted T 1 117 0 51 Predicted T 0 58 0 17 
Common  
signature 289.5 
Predicted N 16 6 16 7 288.8 Predicted N 17 9.7 15 13 Predicted T 1 128 1 127 Predicted T 6 56.3 8 53 
Liver vs Bladder 
   liver→liver bladder→liver   bladder→bladder liver→bladder 
   True N True T True N True T   True N True T True N True T 
All genes 69 Predicted N 21 3 21 32 135 Predicted N 5 13 4 46 Predicted T 0 40 0 11 Predicted T 0 44 1 11 
Common  
signature 51.7 
Predicted N 21 7.1 21 7 54.5 Predicted N 5 2 5 2 Predicted T 0 35.9 0 36 Predicted T 0 55 0 55 
Prostate vs Bladder 
   prostate→prostate bladder→prostate   bladder→bladder prostate→bladder 
   True N True T True N True T   True N True T True N True T 
All genes 55 Predicted N 23 8 16 64 135 Predicted N 5 13 4 54 Predicted T 0 58 7 2 Predicted T 0 44 1 3 
Common  
signature 9.5 
Predicted N 20.3 1.6 18 3 10.1 Predicted N 5 2.5 4 2 Predicted T 2.7 64.4 5 63 Predicted T 0 54.5 1 55 
Lung vs Bladder 
   lung→lung bladder→lung   bladder→bladder lung→bladder 
   True N True T True N True T   True N True T True N True T 
All genes 57 Predicted N 16 17 17 129 135 Predicted N 5 13 5 56 Predicted T 1 117 0 5 Predicted T 0 44 0 1 
Common  
signature 19.1 
Predicted N 14.9 11.9 15 22 19.2 Predicted N 5 3 4 5 Predicted T 2.1 122.1 2 112 Predicted T 0 54 1 52 
The confusion matrixes in the gray shaded regions are used to generate the PPI in shaded regions in Table 3.3 and 
corresponding Table 4. 
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Table B.4  A  List of 109 biomarkers identified in batch I 
Probe Set ID Gene Title Gene Symbol 
39597_at* actin binding LIM protein family, member 3 ABLIM3 
37599_at* aldehyde oxidase 1 AOX1 
34736_at* cyclin B1 CCNB1 
37302_at* centromere protein F, 350/400ka (mitosin) CENPF 
37203_at* carboxylesterase 1 (monocyte/macrophage serine esterase 1) CES1 
32168_s_at* Down syndrome critical region gene 1 DSCR1 
34311_at* glutaredoxin (thioltransferase) GLRX 
1737_s_at* insulin-like growth factor binding protein 4 IGFBP4 
609_f_at* metallothionein 1B MT1B 
36130_f_at* metallothionein 1E MT1E 
31622_f_at* metallothionein 1F MT1F 
39594_f_at* metallothionein 1H MT1H 
41530_at acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-
Coenzyme A thiolase) 
ACAA2 
34050_at acyl-CoA synthetase medium-chain family member 1 ACSM1 
684_at angiotensinogen (serpin peptidase inhibitor, clade A, member 8) AGT 
32747_at aldehyde dehydrogenase 2 family (mitochondrial) ALDH2 
33756_at amine oxidase, copper containing 3 (vascular adhesion protein 1) AOC3 
41306_at amyloid beta (A4) precursor protein-binding, family A, member 2 
binding protein 
APBA2BP 
287_at activating transcription factor 3 ATF3 
201_s_at beta-2-microglobulin B2M 
2011_s_at BCL2-interacting killer (apoptosis-inducing) BIK 
39409_at complement component 1, r subcomponent C1R 
40496_at complement component 1, s subcomponent C1S 
1943_at cyclin A2 CCNA2 
33950_g_at corticotropin releasing hormone receptor 2 CRHR2 
408_at chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating 
activity, alpha) 
CXCL1 
649_s_at chemokine (C-X-C motif) receptor 4 CXCR4 
38772_at cysteine-rich, angiogenic inducer, 61 CYR61 
36643_at discoidin domain receptor family, member 1 DDR1 
33393_at DEAD (Asp-Glu-Ala-As) box polypeptide 19B DDX19B 
32600_at docking protein 4 DOK4 
37827_r_at dopey family member 2 DOPEY2 
34823_at dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing 
protein 2) 
DPP4 
36088_at Down syndrome critical region gene 2 DSCR2 
167_at eukaryotic translation initiation factor 5 EIF5 
1519_at v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) ETS2 
36543_at coagulation factor III (thromboplastin, tissue factor) F3 
1915_s_at v-fos FBJ murine osteosarcoma viral oncogene homolog FOS 
36669_at FBJ murine osteosarcoma viral oncogene homolog B FOSB 
39822_s_at growth arrest and DNA-damage-inducible, beta GADD45B 
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Table B.4 Continued 
290_s_at G protein-coupled receptor 3 GPR3 
35127_at histone cluster 1, H2ae HIST1H2AE 
31521_f_at histone cluster 1, H4k HIST1H4J 
152_f_at histone cluster 2, H4a HIST2H4A 
38833_at major histocompatibility complex, class II, DP alpha 1 HLA-DPA1 
38096_f_at major histocompatibility complex, class II, DP beta 1 HLA-DPB1 
36878_f_at major histocompatibility complex, class II, DQ beta 1 HLA-DQB1 
37039_at major histocompatibility complex, class II, DR alpha HLA-DRA 
36617_at 
inhibitor of DNA binding 1, dominant negative helix-loop-helix 
protein ID1 
676_g_at interferon induced transmembrane protein 1 (9-27) IFITM1 
41745_at interferon induced transmembrane protein 3 (1-8U) IFITM3 
37319_at insulin-like growth factor binding protein 3 IGFBP3 
36227_at interleukin 7 receptor IL7R 
35372_r_at interleukin 8 IL8 
38545_at inhibin, beta B (activin AB beta polypeptide) INHBB 
36355_at involucrin IVL 
1895_at jun oncogene JUN 
41483_s_at jun D proto-oncogene JUND 
217_at kallikrein-related peptidase 2 KLK2 
35118_at lecithin-cholesterol acyltransferase LCAT 
41710_at hypothetical protein LOC54103 LOC54103 
35926_s_at lysozyme (renal amyloidosis) LYZ 
36711_at 
v-maf musculoaponeurotic fibrosarcoma oncogene homolog F 
(avian) MAFF 
33146_at myeloid cell leukemia sequence 1 (BCL2-related) MCL1 
33241_at microfibrillar-associated protein 3-like MFAP3L 
668_s_at matrix metallopeptidase 7 (matrilysin, uterine) MMP7 
870_f_at metallothionein 3 MT3 
36933_at N-myc downstream regulated gene 1 NDRG1 
37544_at nuclear factor, interleukin 3 regulated NFIL3 
190_at nuclear receptor subfamily 4, group A, member 3 NR4A3 
31886_at 5'-nucleotidase, ecto (CD73) NT5E 
31733_at purinergic receptor P2X, ligand-gated ion channel, 3 P2RX3 
32210_at phosphoglucomutase 1 PGM1 
36980_at proline-rich nuclear receptor coactivator 1 PNRC1 
39366_at protein phosphatase 1, regulatory (inhibitor) subunit 3C PPP1R3C 
36159_s_at 
prion protein (p27-30) (Creutzfeldt-Jakob disease, Gerstmann-
Strausler-Scheinker syndrome, fatal familial insomnia) PRNP 
216_at prostaglandin D2 synthase 21kDa (brain) PTGDS 
1069_at 
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase 
and cyclooxygenase) PTGS2 
37701_at regulator of G-protein signalling 2, 24kDa RGS2 
41471_at S100 calcium binding protein A9 S100A9 
33305_at serpin peptidase inhibitor, clade B (ovalbumin), member 1 SERPINB1 
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Table B.4 Continued 
36979_at solute carrier family 2 (facilitated glucose transporter), member 3 SLC2A3 
38797_at solute carrier family 39 (zinc transporter), member 14 SLC39A14 
38994_at suppressor of cytokine signaling 2 SOCS2 
34666_at superoxide dismutase 2, mitochondrial SOD2 
38763_at sorbitol dehydrogenase SORD 
38805_at TGFB-induced factor homeobox 1 TGIF1 
39411_at TCDD-inducible poly(ADP-ribose) polymerase TIPARP 
1715_at tumor necrosis factor (ligand) superfamily, member 10 TNFSF10 
904_s_at topoisomerase (DNA) II alpha 170kDa TOP2A 
32793_at T cell receptor beta variable 19 TRBC1 
38469_at tetraspanin 8 TSPAN8 
40198_at voltage-dependent anion channel 1 VDAC1 
36909_at WEE1 homolog (S. pombe) WEE1 
40448_at zinc finger protein 36, C3H type, homolog (mouse) ZFP36 
32588_s_at zinc finger protein 36, C3H type-like 2 ZFP36L2 
1514_g_at   
1662_r_at   
40487_at Transcribed locus  
A total of 109 biomarkers are identified in more than 70% of leave-one-out cross validation in batch I (batchI-PBs). 
After deleting duplicates, 99 distinct predictive biomarkers are listed below. 
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